AUTHOR INDEX

Abrams, R. 123, 137
Adams, D. O. 105, 108, 119
Ahluwalia, G. S. 114, 120
Ahmed, F. 154, 157, 182, 187, 191, 197, 200, 202, 206, 207
Ahmed, T. 13, 23
Aiello, P. D. 56, 60, 190, 206
Ake, D. V. D. 100, 117
Akerblom, L. 123, 124, 138
Akerman, M. 123, 137
Alacorn, G. S. 247, 248, 263
Alam, T. G. 136, 139
Alberts, D. S. 65, 72
Alexander, J. 267, 270, 275
Alison, D. L. 163–165, 177, 178
Allegra, C. J. 3, 5, 10, 141, 155, 161, 174, 210, 217, 261, 265
Allen, J. B. 257, 265
Allen, L. B. 101, 118
Allende, J. E. 100, 117
Ally, S. 100, 101, 118
Alon, N. 65, 71, 232, 244
Anderele, S. K. 248, 254, 263
Andersen, P. A. 248, 263
Anderson, E. A. 247, 263
Anderson, J. D. 105, 119
Anderson, W. B. 101, 104, 118
Anjali, P. 170, 179
Anthony, B. K. 13, 24
Antony, A. C. 6–9, 11, 14, 16, 20, 21, 24, 26
Appelt, K. 47–60
Arbuck, S. G. 162, 177
Arcoleo, J. 98, 117
Ardalan, B. 162, 175, 176
Arnbrog, F. 232, 245
Arnold, S. T. 114, 120
Aroesty, J. 36, 46
Arrick, B. A. 270, 276
Ashton, W. T. 115, 121
Assaraf, Y. G. 8, 12
Atkinson, T. 182–184, 187
Aull, J. L. 56, 57, 60, 150, 156, 192, 200–202, 207
Avery, T. L. 100, 101, 115, 118, 121
Ayusawa, D. 123, 138, 181, 186
Azari, J. 64, 71

Bachmann, B. 190, 191, 197, 206
Backer, J. M. 98, 117
Bacon, P. E. 123, 124, 128, 137, 138
Bader, H. 7, 12
Baguley, B. C. 33, 46
Bailey, B. D. 13, 23, 231, 236, 241, 244
Baker, P. E. 249, 264
Baker, R. M. 232, 245
Balinska, M. 210, 217, 249, 250, 264
Balis, F. M. 82, 84, 95
Ball, E. 101, 118
Balmanno, K. 167, 170, 171, 178, 179
Banerjee, C. K. 191, 197, 206
Bank, B. B. 267–276
Bansal, G. 257, 265
Baram, J. 3, 5, 10, 141, 155, 161, 174, 210, 217
Bardawill, C. S. 62, 71
Bareham, B. 27, 45
Barenholz, Y. 219, 228
Barner, H. D. 189, 205
Baron, S. 255, 264
Bashor, M. M. 64, 65, 71
Bassendine, M. F. 163, 177
Basu, A. 270, 276
Batist, G. 82, 84, 94
Batisto, J. R. 248, 264
Baugh, C. M. 56, 57, 60, 183, 187, 210, 217
Bayes, P. F. 123, 138
Beardsley, G. P. 5, 10, 141, 148, 155, 156, 209, 216, 261, 265
Beaudette, N. V. 53, 54, 60
Beckage, M. J. 54, 60
Begleiter, A. 268, 276
Belfort, M. 49, 53, 54, 59, 60, 181–183, 186, 187, 189, 205
Bell, D. H. 253, 254, 264
Bell, D. R. 232, 244, 245
Bellamy, W. T. 65, 72
Bellisario, R. L. 53, 60, 141, 155, 181–184, 186, 187, 189, 205
Benda, P. 64, 71
Bender, R. A. 13, 23
Benkovic, S. J. 59, 155, 205, 217
Bennett, L. L., Jr. 191, 197, 206
Berg, P. 123, 137
Berridge, M. J. 27, 45
Bertino, J. R. 7, 8, 11, 12, 17, 24, 25, 162, 175, 183, 184, 187, 191, 206, 231, 236, 241, 243, 244, 277–285
Betteridge, R. F. 47, 59, 165, 178
Betts, C. R. 75, 94

Beutler, B. 69, 72
Beverley, S. M. 181, 186
Biedler, J. L. 232, 244
Billingham, L. M. 247, 248, 263
Bishop, J. 82, 84, 95
Bishop, J. A. M. 163, 167, 170, 177, 178
Bishop, Y. 231, 235, 244
Bisset, G. 167, 170, 178, 179
Bisson, L. F. 190, 206
Blair, J. A. 177
Blair, O. C. 88, 91, 95
Blakley, R. L. 24, 59, 142, 155, 156, 205, 215, 217
Blankenship, N. M. 16, 25
Blumenstein, M. 54, 60
Bobzien, W. F. 13, 24
Bodemer, W. 182, 186
Boezi, J. A. 123, 138
Boldizar, M. 91, 95,
Boldt, D. H. 82, 84, 95
Boltz, R. C. 115, 121
Boritzki, J. J. 28, 35, 36, 46
Bork, E. 163, 177
Borsa, J. 162, 175
Boschelli, D. 7, 11, 212, 215, 217, 261, 265
Boswell, K. H. 100, 118
Bourne, H. R. 97, 117
Bradford, M. M. 191, 206
Bradley, G. 232, 244
Bradshaw, T. P. 191, 207
Brahmi, Z. 109, 120
Branda, R. F. 13, 24
Brandt, J. E. 6, 8, 11
Bray, M. A. 252, 264
Brickenden, A. 101, 118
Briddell, R. A. 6, 8, 11
Briggs, W. T. 13, 24
Brink, L. 7, 12, 19, 25
Brockman, R. W. 191, 197, 206
Brooks, P. M. 254, 264
Broom, A. D. 115, 121
Browman, G. P. 162, 175
Brown, P. C. 231, 235, 236, 244
Brown, S. J. 141, 155, 161, 163, 164, 174, 177
Bruce, W. R. 91, 95
Bruno, E. 6, 8, 11
Brunton, L. L. 64, 71
Buckley, L. M. 262, 265
Buick, R. N. 231, 232, 236, 241, 244
Bunni, M. 161, 174, 212, 214, 217
Burchall, J. J. 24, 186, 217
Burchenal, J. H. 104, 119
Burgen, A. S. V. 59, 175, 205
Buscaglia, M. D. 162, 175
Calabrese, L. H. 247, 263
Callahan, L. F. 248, 263
Calvert, A. H. 47, 59, 141, 155, 161–179, 209, 216
Cameron, K. R. 182, 186
Campbell, I. L. 64, 71
Campbell, M. T. 101, 118
Cancilla, P. 14, 24
Cantley, L. 101, 118
Cantwell, B. M. 163, 177
Capdevila, A. 6, 11
Caplan, S. 270, 276
Caput, D. 181, 186
Caradonna, S. J. 162, 176
Caras, I. W. 123, 136–139
Cardarelli, C. O. 65, 72
Carman, M. D. 231, 236, 241, 244, 277, 284
Carney, D. N. 231, 236, 241, 244
Carrico, C. K. 162, 176
Carroll, A. 104, 119
Carter, G. L. 123–139
Cashmore, A. R. 7, 8, 11, 12, 277, 280, 284, 285
Caspers, J. 219, 227
Caspi, D. 260, 262, 265
Caston, J. D. 14, 24
Catovsky, D. 231, 243
Cavalli, F. 163, 178
Cerna, I. 162, 175
Chabner, B. A. 3–12, 13, 23, 141, 155, 161, 162, 174–176, 210, 217, 261, 265
Chahwala, S. B. 101, 118
Chambers, P. 167, 178
Chan, A. K. M. 123, 138
Chan, K. K. 164, 178
Chandra, P. 284
Chang, C. C. 123, 138
Chang, C.-H. 123, 137
Chang, T.-D. 232, 244
Chang, Y. 100, 118
Chang, Y. M. 277–285
Chatelain, P. 219, 227
Chavaudra, N. 39, 46
Chello, P. L. 13, 24
Chen, C.-J. 65, 71
Cheng, Y. 191, 206
Cheng, Y.-C. 123, 137, 162, 170, 176, 179
Chin, E. C. 65, 71
Cho-Chung, Y. S. 100, 101, 118
Chou, T. C. 212, 217
Christophers, E. 254, 264
Chrzeszczyk, A. 220, 222, 228
Chu, B. C. F. 149, 156
Chu, F. K. 181, 183, 186
Chubb, S. 43, 46

Cihak, A. 162, 176
Cipollo, K. L. 54, 60
Cisneros, R. J. 189, 205
Clair, T. 100, 101, 118
Clapham, D. A. 97, 117
Clark, D. P. 65, 71
Clark, G. M. 82, 84, 95
Clark, R. L. 248, 263
Claypool, R. G. 247, 263
Cleland, W. W. 145, 156
Clendennin, N. J. 141, 155, 161, 174
Clift, S. M. 123, 138
Clough, J. C. 247, 263
Coates, A. 82, 84, 95
Coblyn, J. S. 247, 248, 257, 263
Coffey, R. G. 105, 119
Cohen, F. E. 260, 265
Cohen, M. B. 113, 120, 162, 175
Cohen, S. S. 189, 205
Colamonici, O. 101, 118
Coldmann, A. J. 242, 245
Collins, J. M. 82, 84, 94
Colman, P. D. 164, 178
Combe, B. 255, 264
Combs, C. A. 27, 45
Conelly, K. 162, 175
Connelly, M. C. 102, 110, 119
Conners, T. A. 118, 162, 175
Cook, P. D. 28, 35, 36, 46
Cooney, D. A. 75, 93, 94, 114, 120, 162, 176
Cooper, S. M. 262, 265
Cooper, B. A. 10, 178, 179, 217, 264
Cordingley, J. S. 181, 186
Corin, R. E. 13, 23
Cornwell, M. M. 65, 72
Coronello, M. 280, 285
Cory, A. H. 46
Cory, J. G. 46, 123–139, 261, 265
Cottam, H. B. 97–121
Courdi, A 39, 46
Cowan, K. H. 65, 71
Crabtree, G. W. 100, 118
Craddock, J. G. 248, 254, 263
Crawford, E. J. 194, 207, 231, 243
Creaven, P. J. 162, 177
Cromartie, W. J. 248, 254, 263
Crossley, P. H. 163, 177
Crumm, M. 194, 207
Cucchi, C. A. 7, 12
Culham, C. A. 82, 84, 95
Curt, G. A. 141, 155, 161, 174, 231, 236, 241, 244
Curtin, N. J. 163, 177
Cuttino, J. 248, 263
Cutts, J. M. 113, 120
D'Incalci, M. 163, 178
Da Costa, M. 7, 11, 12, 19, 25
Dagan, A. 219, 227
Dahl, S. L. 247, 248, 263
Dahllöf, B. 232, 244
Dale, G. L. 68, 72
Dale, R. M. K. 146, 153, 156
Dallas, W. S. 182, 187
Dalley, N. K. 105, 119
Dameshek, W. 277, 284
Danenberg, K. D. 162, 176
Danenberg, P. V. 47, 53, 54, 57, 59, 60, 141, 155, 162, 176, 189, 190, 205,
Darnell, B. 255, 264
Daron, H. H. 56, 60
Das, K. C. 231, 244
Davey, R. A. 232, 244
David, M. M. 62, 71
Davies, S. A. 101, 118
Davis, B. J. 142, 156
Davis, D. C. 165, 178
Davis, L. C. 165, 178
Davis, L. J. 47, 59
Davis, W. 177
Day, J. L. 162, 176
De Franco, A. L. 198, 120
De Kruijff, B. 219, 227
Dean, P. D. G. 197, 207
DeBruyn, C. H. M. M. 177, 179
DeGraw, J. I. 13, 23, 24, 281, 285
Deits, T. 190, 206
Dejong, D. J. 247, 263
Delcamp, T. J. 14, 17, 24, 25
Dembo, M. 13, 24, 62, 71, 210, 217
Dempsey, R. D. 257, 265
Deng, T. 182, 187
Denny, W. A. 33, 46
Desouza, J. J. V. 114, 120
Dethlefson, L. A. 27, 45
Deuchars, K. 65, 71, 232, 244
Deutsch, E. 243
Dev, I. K. 182, 187
Diamanstein, T. 250, 251, 264
Diamond, L. K. 277, 284
Diddens, H. 231–245
Diddens, K. 163, 178
Dietz, J. 64, 71
Dimartino, M. J. 259, 265
Dinarello, C. A. 257, 260, 265
Dion, R. L. 75, 93
Doig, M. T. 161, 174, 191, 197, 206, 214, 217
Doig, M. V. 252, 264
Dolnick, B. J. 191, 206
Dolnick, D. J. 184, 187
Donato, H. 150, 156, 161, 174, 202, 207, 214, 217

Donohue, D. R. 231, 243
Donsbach, R. C. 13, 17, 23
Dorr, R. T. 65, 72
Dott, K. 114, 121
Dowden, G. 232, 244
Dower, W. J. 231, 236, 241, 244
Drake, J. C. 3, 5, 10, 141, 155, 161, 174, 210, 217, 231, 236, 241, 244, 261, 265
Dreyer, R. N. 280, 285
Dreyer, W. J. 221, 228
Duarte-Karim, M. 219, 227
Dube, S. K. 277, 284
Duch, D. 209, 216
Duffy, T. 231, 236, 241, 244
Dunlap, R. B. 53, 54, 57, 59, 60, 144, 145, 151–154, 156, 157, 162, 175, 181, 182, 186, 187, 189–207
Durand, R. E. 27, 45
Dushinsky, R. 189, 205
Dutschman, G. E. 170, 179

Eakin, M. A. 47, 59, 165, 178
Earnshaw, M. 163, 177
Eddy, H. A. 27, 45
Eddy, J. L. 82, 84, 94
Edelman, J. 247, 263
Edwards, J. C. W. 249, 264
Egan, E. M. 162, 176
Eggar, M. J. 247, 248, 263
Ehrenberg, A. 123, 124, 138
Eibl, B. 7, 11
Elford, H. L. 129, 139
Elford, R. M. 129, 139
Ellenberger, T. E. 181, 186
Ellingsworth, L. 257, 265
Ellis, P. D. 53, 59
Elslager, E. 104, 119
Elving, P. J. 207
Elwood, P. C. 3–12, 14, 21, 24, 26
Ensminger, W. B. 24, 148, 156, 161, 174, 186, 217
Erbe, J. 64, 71
Eriksson, S. 123, 137, 138
Espinoza, L. R. 261, 265
Esposito, M. 223, 228
Estival, A. 101, 104, 118
Ettinger, L. J. 82, 84, 95

Fabry, M. 123, 137
Faderan, M. A. 102, 119
Fain, J. N. 98, 117
Falchuk, K. R. 248, 257, 263
Farber, C. M. 267, 270, 276
Farber, S. 227, 284
Fauci, A. 119
Ferguson, K. M. 97, 113, 117, 248, 250, 264
Ferone, R. 209, 216
Finch, R. A. 100, 118
Fine, R. L. 3, 10, 82, 84, 94, 210, 217, 261, 265
Finer-Moore, J. S. 50, 51, 29, 141, 154, 155
Finley, A. 6, 7, 9, 11
Fischer, G. A. 162, 175, 231, 243
Fishbach, M. 255, 264
Fishel, B. 260, 262, 265
Fisher, M. H. 170, 179
Fitzhugh, A. L. 3, 10
Flaks, J. G. 189, 205
Fleckenstein, B. 182, 186, 187
Fleischer A. E. 123, 137
Fleischman, L. F. 101, 118
Fletcher, J. J. 247, 263
Fletcher, S. R. 141, 155
Flinn, A. 165, 178
Flintoff, W. F. 8, 12, 13, 23
Fojo, A. T. 65, 71, 232, 244
Fok, J. J. 219, 227
Follmann, H. 190, 191, 197, 206
Ford-Hutchinson, A. W. 252, 260
Forlenza, T. J. 267, 268, 273, 275
Forrest, M. J. 254, 264
Forsch, R. A. 164, 178
Forssen, E. A. 219, 227
Fox, D. A. 247, 248, 263
Fox, R. 82, 84, 95
Fox, R. M. 44, 46
Fram, R. 162, 176
Franko, A. J. 27, 45
Frappier, L. 123, 137
Frasca, V. 182, 185, 187
Fraser, P. A. 247, 248, 263
Fraser, R. A. 248, 257, 263
Frei, E. 231, 235, 244
Freireich, E. J. 253, 264
Freisheim, J. H. 6, 7, 11–26, 145, 156, 181, 186, 248, 250, 264
Frese, G. 231–245
Fridland, A. 102, 110, 119
Friedkin, M. 145, 154, 156, 157, 194, 207, 231, 243
Frimatkandada, S. 231, 236, 241, 244
Fritsch, E. F. 233, 245
Fry, D. W. 28, 35, 36, 46, 65, 72
Fujitaki, J. M. 97–121
Fuks, Z. 219, 228
Fukumoto, Y. 113, 120
Furlong, B. M. 27, 45
Furness, M. E. 13, 23, 162, 175
Furst, D. E. 247, 254, 261, 263

Fyfe, J. A. 110, 120
Fyfe, M. J. 62, 71

Gabizon, A. 219, 228
Gabrio, B. W. 231, 243
Galivan, J. H. 7, 11, 13, 23, 56, 57, 60, 141, 144, 155, 156, 182, 184, 187, 189, 205, 209–217, 248–250, 261, 263 264
Ganapathi, R. 219, 228
Gantas, L. J. 235, 245
Garvey, E. P. 141, 155
Gaumont, Y. 5, 10, 170, 170, 191, 206, 209, 210, 216, 217
Gavin, J. B. 33, 46
Gebeyehu, G. 75, 94
Gehan, E. A. 253, 264
Gekeller, V. 231–245
Gerlach, E. 243
Gerlach, J. H. 232, 244, 245
Germain, B. F. 261, 265
Gewirt, D. A. 13, 24
Ghosh, T. K. 112, 120
Giampaolo, T. 100, 118
Gibbons, J. J. 255, 265
Gill, D. L. 112, 120
Gillis, S. 249, 264
Gilman, A. 277, 284
Gilman, A. G. 97, 113, 117
Ginier, M. 163, 178
Girard, M. 114, 121
Glass, D. N. 247, 248, 263
Glatzner L. 123, 138
Glazer, R. I. 75, 93, 94, 162, 176
Gleason, M. C. 65, 72
Gold, M. R. 108, 120
Goldenberg, A. G. 268, 276
Goldie, J. H. 242, 245
Goldin, A. 231, 243
Goldman, D. I. 162, 174
Goldman, I. D. 6, 8, 11, 13, 17, 19, 23–25, 62, 71
Goodman, L. S. 277, 284
Goodman, M. G. 115, 121
Goodman, M. J. 277, 284
Goormaghtigh, E. 219, 227
Gopalakrishna, R. 101, 104, 118
Goren, D. 219, 228
Gornall, A. G. 62, 71
Gotoh, O. 181, 186
Gottesman, M. M. 65, 71, 72, 232, 244
Gottlieb, J. A. 219, 227
Goulian, M. 162, 176
Goutas, L. J. 8, 12, 13, 23, 62, 71, 281, 285
Graslund, A. 123, 124, 129, 138, 139
Graves, D. J. 192, 207
Greco, W. R. 36, 38, 46, 211, 217
Green, R. M. 82, 84, 95
Greenblatt, D. J. 84, 94
Griffiths, J. R. 167, 179
Grimshaw, C. E. 5, 6, 10
Grindey, G. B. 43, 46, 161, 174, 209, 210, 216, 217
Gross, J. F. 36, 46
Grossberg, H. 267, 268, 273, 275
Grumont, R. 181, 186
Grygiel, J. 82, 84, 94, 95
Grzelakowska-Sztabert, B. 17, 25, 163, 170, 177, 179
Guarino, D. U. 53, 60, 141, 155, 181, 186, 189, 205
Gubner, R. 247, 262
Gudas, L. J. 123, 138
Gudauskas, G. A. 242, 245
Guichard, M. 39, 46
Gultadauria, M. 247, 248, 263
Gumbrell, L. A. 163, 177
Gunderson, L. E. 145, 156
Gupta, S. 119
Gupta, V. S. 190, 206
Guschlbauer, W. 190, 206
Guy, G. 114, 121

Hacker, M. P. 270, 276
Hadden, J. W. 105, 119
Hadjiolov, A. A. 162, 176
Hadjiolova, K. V. 162, 176
Haertle, T. 190, 206
Hakala, M. T. 211, 217
Hall, A. 101, 118
Hall, B. T. 13, 23
Hall, T. C. 17, 25, 162, 175, 231, 243
Hamada, H. 65, 71
Hamamori, Y. 113, 120
Hamelehle, K. L. 28, 35, 46
Hamer, D. H. 270, 276
Hamilton, T. A. 105, 108, 119
Handgretinger, R. 231–245
Hanna, N. L. 259, 265
Hanrahan, P. S. 262, 265
Hansen, H. H. 163, 177
Hansen, S. I. 6, 11, 19–21, 25
Hanson, R. W. 100, 118
Harding, N. G. L. 145, 156, 181, 186, 189, 191, 201, 205
Hards, R. G. 123, 138
Hardy, L. W. 50, 51, 59, 141, 154, 155
Hari, L. I. 13, 23
Harland, S. J. 47, 59, 163, 165, 177, 178
Harnett, M. M. 97, 105, 107, 117, 119, 120
Harper, G. R. 114, 120

Harpers, M. E. 234, 245
Harping, L. M. 14, 17, 25
Harrap, K. R. 13, 23, 36, 46, 47, 59, 119, 141, 155, 161–179, 235, 245, 268, 276
Harrington, P. J. 141, 155, 261, 265
Harris, A. L. 163, 177, 267, 270
Hart, L. I. 13, 23, 162, 163, 175, 177, 235, 245
Hartley, B. S. 182–184, 187
Hartmann, D. H. 232, 244
Hartshorn, J. N. 82, 84, 95
Hashimoto, E. 98, 100, 117
Haspel, H. E. 13, 23
Hatefi, Y. 191, 206
Haugh, L. D. 82, 84, 95
Haynes, R. H. 182, 187
Hayter, A. J. 47, 59, 165, 167, 178
Heasely, L. E. 64, 71, 98, 115–117
Heerema, N. 75, 76, 78–84, 87–91, 94
Heidelberger, C. 54, 60, 141, 155, 162, 176, 189, 190, 205
Heideman, R. L. 82, 84, 95
Hellwich, M. 64, 71
Hellwich, U. 64, 71
Hemmings, B. A. 100, 117
Henderson, D. 270, 276
Henderson, E. S. 13, 24
Henderson, G. B. 5, 6, 8, 10, 11, 13, 16–18, 24, 25, 61–72, 147, 153, 156
Hennen, W. J. 101, 115, 118, 121
Henze, G. 231–245
Herrera, L. 162, 177
Herrick, D. 162, 176
Hersch, M. R. 82, 84, 95
Hertel, L. 43, 46
Hescheler, J. 98, 117
Hickson, I. D. 267, 270, 275
Higashijima, T. 97, 113, 117
Higashikubo, R. 27, 45
Hildebrand, J. 219, 227
Hill, B. T. 162, 175, 268, 270, 276
Hillcoat, B. L. 145, 156
Hoang, K. 3, 5, 10, 210, 217
Hoffbrand, A. V. 231, 245
Hoffman, R. 6, 8, 11, 75–85, 87–92, 94, 101, 102, 119
Hoglind, J. A. 161, 174
Holdsworth, D. E. 247, 248, 257, 263
Holienberg, J. S. 82, 84, 95
Hollan, S. R. 88, 91, 95, 101, 118
Holm, J. 6, 11, 19–21, 25
Holmes, R. E. 114, 121
Holy, A. 54, 60
Honess, R. W. 182, 186
Hopper, W. E., Jr. 145, 151, 152, 156
Horanyi, M. 88, 91, 95, 101, 118
Horne, D. W. 13, 24
Horns, R. C. 231, 236, 241, 244
Hoth, D. F. 75, 84, 94
Houghton, J. A. 162, 176, 190, 191, 206
Houghton, P. J. 162, 176, 190, 191, 206
Houslay, M. D. 101, 118
Hryniuk, W. M. 162, 175, 278, 284
Hsaiao, M. C. 170, 179
Hsiang, Y.-H. 267, 268, 270, 273, 275, 277
Hu, S. K. 249, 264
Huang, C. 220, 228
Huang, C.-h. 220, 222, 228
Huennekens, F. M. 5, 6, 10, 17, 25, 61, 65, 68, 70, 71, 145, 156, 162, 175, 181, 186, 189, 191, 201, 205, 206, 231, 235, 243, 245, 260, 265
Hughes, L. R. 161–179
Hugli, T. E. 252, 264
Huigen, Y. M. 219, 227
Hummel, J. P. 221, 228
Humphreys, S. R. 231, 243
Hunt, D. A. 257, 265
Hurlbert, R. B. 123, 137
Hutchinson, M. 270, 276
Hutchison, D. J. 231, 243
Hynes, J. 183, 187, 191, 197, 206

Idhe, D. C. 82, 84, 94
Ikegami, T. 88, 91, 95, 101, 102, 118, 119
Imam, A. M. 163, 177
Ingraham, H. A. 162, 176
Isbister, J. P. 232, 244
Ishihara, M. 219, 228
Ivanetich, K. M. 182, 187
Iwakura, K. M. 182, 187
Iwata, K. 123, 138

Jackman, A. L. 47, 59, 141, 155, 161–179, 209, 216
Jackson, R. C. 13, 23, 27–46, 75, 93, 162, 163, 175, 177, 210, 217, 231, 233–236, 243–246
Jackson, S. T. M. 162, 175
Jacob, H. S. 13, 24
Jacobsen, D. W. 5, 6, 10
Jaffe, N. 231, 235, 244
Jahnsen, T. 101, 118
Jakoby, W. B. 205, 207
Jakway, J. P. 108, 120
James, O. F. W. 163, 177
Jard, S. 64, 71
Jastreboff, M. 277, 284

Jayaram, H. N. 75–85, 87–94, 101, 102, 114, 119, 120
Jenkins, J. F. 82, 84, 94
Jerkunica, I. 190, 206
Jewell, M. E. 115, 121
Jiang, B.-Z. 270, 276
Johns, D. G. 75, 93, 94, 114, 120
Johnson, G. L. 98, 115–117
Johnson, L. F. 182, 187
Johnson, T. B. 211, 212, 215–217
Johnson, W. J. 259, 265
Jolivet, J. 3, 10, 141, 155, 161, 174, 210, 217
Jolivet, K. H. 231, 236, 241, 244
Jolley, W. B. 97–121
Jones, C. 209, 216
Jones, M. O. 50, 51, 59, 141, 154, 155, 161, 163, 164, 174
Jones, T. R. 47, 59, 141, 155, 161, 163–165, 167, 170, 177–179
Judson, I. R. 163, 177
Juranka, P. F. 232, 241, 242, 244
Jurnak, F. 60

Kailey, J. M. 65, 72
Kallman, R. F. 27, 45
Kalman, T. I. 170, 179, 278, 280, 284, 285
Kamen, B. A. 6, 7, 11, 14, 24
Kaminska, B. 170, 179
Kane, M. A. 6, 7, 9, 11, 14, 21, 24, 26
Kaneda, S. 181, 186
Kanganis, D. 267, 268, 270, 273, 275, 276
Kao-Shan, C. S. 231, 236, 241, 244
Kapusta, M. A. 257, 265
Karakousi, C. 232, 245
Kartner, N. 65, 71, 232, 244, 245
Kashiwado, T. 255, 257, 264
Katsaros, D. 100, 101, 118
Katsaros, K. 100, 118
Kaufman, B. T. 191, 206
Kaufmann, R. J. 231, 235, 236, 244
Kawata, M. 182, 187
Kaye, S. B. 163, 177
Kazumitsu, U. 65, 71
Keeffe, E. B. 16, 25
Kefford, R. F. 44, 46
Kelleher, D. J. 98, 115–117
Kelleher, L. E. 8, 12, 13, 23, 235, 245
Keller, P. M. 110, 120
Kelley, J. A. 75, 94
Kelley, S. D. 27, 45
Kelly, S. L. 270, 276
Kelly, W. N. 179
Kemper, H. L. 27, 45
Kempny, M. 170, 179
Kempton, R. J. 14, 17, 25
Keng, P. C. 33, 46
Kenny, E. 182–184, 187
Kerr, I. G. 82, 84, 94
Kerwar, S. S. 7, 11, 212, 215, 217, 247–265
Kesevan, V. 161, 174, 214, 217
Kessel, D. 17, 25, 162, 175, 231, 243
Kessler, J. F. 88, 91, 95
Keyomarsi, 162, 177
Kharbanda, S. M. 113, 120
Kieny, M. P. 114, 121
Kincade, R. S. 6, 11
King, C. 64, 71
King, S. A. 75, 84, 94
Kini, G. D. 105, 115, 119, 121
Kiris, J. J. 114, 120
Kirschenbaum, S. 267, 268, 273, 275
Kisliuk, R. L. 5, 10, 53, 54, 60, 151, 156, 170, 179, 191, 195, 206, 207, 209, 210, 216, 217
Klaus, G. G. B. 97, 105, 107, 117, 119, 120
Klecker, R., Jr. 82, 84, 94
Klein, T. E. 14, 17, 25
Klohs, W. D. 27, 45, 65, 72
Klubes, P. 162, 175
Kneebone, P. 75–85, 87–91, 94
Knight, C. B. 3–12
Knight, R. D. 88, 91, 95, 113, 120
Knowles, D. 267, 268, 273, 275
Kobayashi, T. 98, 100, 117
Koeller, J. M. 82, 84, 95
Kohler, W. 7, 12
Kohn, M. C. 36, 38, 46
Koizumi, K. 16, 25
Koizumi, K. T. 16, 25
Koizumi, S. 141, 155
Koizunic, S. 161, 174
Koja, S. 190, 206
Kojima, N. 219, 222, 223, 228
Kolhouse, J. F. 6, 7, 9, 11, 14, 16, 20, 21, 24, 26
Koller, C. A. 44, 46
Kollhoff, I. M. 207
Kondo, T. K. 69, 72
Koo, G. C. 115, 121
Kote, Z. 88, 91, 95, 101, 118
Kotzin, B. L. 247, 263
Kourounakis, L. 257, 265
Krakoff, I. R. 82, 84, 95
Kraut, J. 55, 60
Kremer, J. M. 247, 248, 254, 261, 263
Kremmer, T. 88, 91, 95, 101, 118
Krishan, A. 219, 228
Krishnan, S. R. 6, 11

Krzyzanowski, L. 170, 179
Kufe, D. M. 113, 120
Kufe, D. W. 162, 176
Kuhn, J. G. 82, 84, 95
Kumar, H. P. 6, 8, 11, 153, 156
Kurita, S. 231, 243
Kuttan, R. 75, 94, 102, 114, 119

Labarca, C. 233, 285
Land, H. 101, 102, 118
Lange, B. L. 82, 84, 95
Langenbach, R. J. 162, 176, 190, 205
Langer, P. R. 147, 156
Langerman, N. 54, 60
Lankinen, H. 123, 124, 138
Lapat-Polasko, L. 182, 185, 187
Lapis, E. 75–85, 87–92, 94, 101, 119
Larson, S. B. 105, 119
Lasater, L. 128, 138
Lawton, A. R. 115, 121
Lazarus, H. 148, 156
Lazo, J. S. 24, 270, 276
Leary, R. P. 53, 60
Lecocq, J. P. 114, 121
Lee, H. J. 114, 120
Lee, J. K. 248, 263
Lefendre, P. W. 247, 263
Leffler, H. 232, 244
Lefrak, E. A. 219, 227
Lenty, A. A. 231, 243
Leong, J. 182, 187
Leopold, W. R. 65, 72
Levan, G. 232, 244
Levinson, B. B. 123, 137
Levinson, B. H. 123, 138
Lewis, C. A. 53, 59, 145, 151, 152, 156, 162, 175, 189, 205
Lewis, W. H. 123, 138
Leyland-Jones, B. 75, 84, 94
Li, W. W. 277–285
Lichtenstein, J. 189, 205
Lichtenstein, N. S. 17, 25
Lieberman, I. 123, 137
Liebes, L. F. 267, 270, 275, 276
Lien, E. J. 123, 128, 138
Liepnieks, J. J. 102, 119
Lin, A. L. 129, 139
Lin, J. 277–285
Lincoln, T. L. 36, 46
Ling, V. 65, 71, 232, 241, 242, 244, 245
Lippman, S. M. 88, 91, 95
Litterst, C. L. 114, 120
Little, P. F. R. 163, 177
Liu, L. F. 267, 268, 273, 275, 276
Livingston, D. C. 146, 153, 156
Lo, W. W. Y. 102, 119
Lochrie, M. A. 97, 98, 117
Lockshin, A. 54, 60, 162, 176
Loeb, M. R. 189, 205
Loeble, R. B. 57, 60, 144, 156, 190–194, 205
Logosky, P. A. 182, 187
Loh, E. 162, 176
Loose, H. 163, 177
Lorenzo, A. V. 13, 24
Lowe, C. R. 197, 207
Lu, Y. 190, 206
Lucas, D. L. 88, 91, 95, 102, 105, 113, 119, 120
Lucas, J. 255, 265
Luggen, M. C. 247, 248, 263
Luhrs, C. A. 7, 11, 19, 21
Lui, M. S. 29, 46, 76, 94, 102, 119
Luk, C. K. 33, 46
Lutz, R. 261, 265
Lyngbye, J. 6, 11, 19–21, 25
Lyon, J. A. 144, 150, 156, 190–194, 201, 202, 207

Ma, D. D. F. 232, 244
Macara, I. G. 101, 118
Macaulay, V. 163, 177
MacKenzie, A. H. 247, 262, 263
Mackertich, S. M. 232, 244
Major, P. P. 162, 176
Malaise, E. P. 39, 46
Maley, F. 49, 53, 54, 56, 57, 59, 60, 141, 144, 155, 156, 181–187, 189, 205, 209, 216
Maley, G. F. 49, 53, 54, 59, 60, 141, 144, 155, 156, 181– 187, 189, 205
Malspeis, L 114, 120
Mandel, H. G. 162, 175, 176
Maniatis, T. 233, 245
Mann, G. J. 44, 46
Mansell, M. M. 124, 138
Manteuffel-Cymborowska, M. 170, 179
Manyak, C. L. 115, 121
Marcell, P. D. 14, 24
Marimi, A. 232, 245
Maroda, S. J. 162, 176
Maroun, J. A. 82, 84, 95
Marquez, V. E. 75, 94
Marshall, C. J. 101, 118
Marsham, P. R. 167, 178
Martin, D. W., Jr. 123, 136–139
Martin, E. 146, 153, 156
Martinsson, T. 232, 244
Mason, J. T. 220, 228
Matherly, L. H. 6, 8, 11, 13, 24, 162, 174
Mathews, C. K. 162, 175

Matsumoto, S. S. 44, 46, 97–121
Matthews, D. A. 47–60, 181, 186
Matthews, R. G. 56, 60, 190, 206
Maxwell, R. J. 167, 179
Maybaum, J. 113, 120, 162, 175, 176
Mayer, M. 231, 243
Mayer, S. E. 64, 71
Mazarer, D. J. 247, 263
Mazzei, T. 280, 285
McAlinden, T. P. 20, 26
McBurney, M. W. 261, 265
McCartney-Francis, N. 257, 265
McClarty, G. M. 123, 136, 1387, 139
McClintock, D. K. 253, 254, 264
McCloskey, T. M. 65, 72
McCormack, J. A. 82, 84, 95
McCormick, D. B. 206
McCormick, J. I. 14, 18, 25
McDonald, J. S. 162, 176
McElleken, A. 182, 187
McElwain, T. J. 163, 177
McGhee, K. G. 165, 178
McGrogan, M. 231, 235, 236, 244
McGuire, J. J. 278, 280, 281, 284, 285
McKay, I. 101, 118
McKee, S. A. 110, 120
McKernan, P. A. 114, 120
McLennan, M. 277, 284
McPherson, A. 50
Medina, W. D. 277, 284
Meek, T. D. 141, 155
Meeker, B. E. 91, 95
Mehlman, L. 277, 284
Mehtha, A. P. 170, 179
Meier, G. 36, 46
Meister, A. 155, 157
Meldrum, J. B. 190, 206
Melera, P. W. 232, 244
Melink, T. J. 82, 84, 95
Mercer, R. D. 277, 284
Meshorer, A. 219, 228
Meunier, P. C. 259, 265
Meurer, L. C. 115, 121
Meyers, M. B. 232, 244
Meyn, R. E. 45
Meyskens, F. L., Jr. 88, 91, 95
Mikanagi, K. 179
Miller, D. R. 247, 263
Miller, H. 100, 117
Miller, J. P. 100, 118
Miller, L. C. 257, 260, 265
Miller, R. G. 27, 45
Milsted, A. V. 163, 177
Mines, L. S. 6, 11, 13, 23, 18, 25, 62, 71
Mini, E. 8, 12, 277, 280, 284, 285
Minna, J. D. 231, 236, 241, 244
Misra, U. D. k. 231, 243
Mitchell, B. S. 44, 46
Mitcho, Y. 249, 264
Mittelman, A. 162, 177
Miyasaka, N. 253, 264
Miyoshi, M. 190, 206
Moccio, D. M. 8, 12, 13, 23, 62, 71, 235, 245, 281, 285
Moissec, P. 255, 257, 264
Montagnier, L. 114, 121
Montague-Wilke, B. 61, 63, 70
Montfort, W. R. 50, 51, 59, 141, 154, 155
Montgomery, J. 123, 138
Montgomery, J. A. 7, 12, 13, 23, 24, 186, 217
Moore, E. C. 123, 137
Moore, M. A. 154, 157, 182, 187, 191, 200, 202, 206, 207
Moran, R. 167, 170, 178
Moran, R. G. 5, 7, 10, 12, 141, 155, 162, 164, 176–178, 209, 216, 261, 265
Moroson, B. A. 8, 12, 277, 280, 284, 285
Moscow, J. A. 65, 71
Moser, K. 243
Mosmann, T. 146, 153, 156
Muggia, F. M. 174, 219, 227
Muirhead, K. A. 259, 265
Mulkins, M. A. 162, 176
Mullaney, J. M. 112, 120
Muller, M. 177, 179
Muller-Eberhard, H. J. 252, 264
Muneyama, K. 100 118
Munro, J. B., III. 123, 137
Murayama, K. 102, 119
Murphree, S. A. 219, 227
Murphy, D. 219, 227
Murray, B. K. 114, 120
Murthy, B. R. 5, 10
Myers, C. E. 162, 175, 176

Nagahara, K. 105, 119
Nagainis, C. R. 8, 12, 13, 23
Nagamine, Y. 100, 117
Nahas, A. 17, 25
Nair, I. G. 170, 179
Nair, M. G. 5, 10, 170, 179, 209, 211, 212, 215–217
Najfeld, V. 6, 7, 9, 11
Nakagawa, J. 100, 117
Nakamura, S. 98, 100, 117
Nakamura, T. 255, 264
Nakata, R. 190, 206
Nakayama, K. 162, 176
Nanavati, N. T. 170, 179
Narayanan, R. 278, 284
Narayanan, V. L. 75, 94, 101, 118

Narindrasorasak, S. 101, 118
Nathan, C. F. 270, 276
Natsumeda, Y. 75–85, 87–92, 94, 95, 101, 102, 107, 114, 118, 119
Naydenova, Z. G. 162, 176
Nazarbaghi, R. 141–157
Neckers, L. 110, 101, 118
Neef, V. G. 231, 243, 260, 265
Neer, E. J. 97, 117
Neumann, M. 232, 244
Newby, A. C. 110, 120
Newell, D. R. 47, 59, 161–179, 209, 216
Newman, G. C. 220, 222, 228
Newman, R. A. 82, 84, 95
Nguyen, B. T. 114, 120
Nicander, B. 171, 179
Nichols, A. P. 13, 23
Nichols, C. R. 75, 76, 78–85, 87–91, 94, 101, 102, 119
Nichols, E. A. 115, 121
Nicolay, K. 219, 227
Niethammer, D. 13, 23, 162, 163, 175, 177, 231–245
Nikhioka, K. 179
Niller, H.-H. 182, 186
Nimec, Z. 7, 11, 209–217, 249, 250, 264
Nishida, K. 16, 25
Nishiyama, K. 98, 100, 117
Nishizuka, Y. 98, 101, 117
Nixon, P. F. 17, 25, 145, 156
Nord, L. D. 97–121
Nordstrom, D. M. 248, 263
North, J. A. 114, 120
Nowak, B. 43, 46
Nozawa, Y. 223, 228

O'Callaghan, P. 254, 264
O'Connell, K. 114, 120
O'Connor, B. M. 165, 167, 170, 178
O'Connor, J. 167, 178
O'Dell, J. R. 247, 263
O'Dwyer, P. J. 75, 84, 94
Oatley, S. J. 47–60
Oekner, R. K. 16, 25
Ogawa, M. 219, 227
Ohki, K. 223, 228
Ojawa, S. 98, 115–117
Ojo-Amaize, E. 97–121
Olah, E. 75–77, 85, 87–92, 94, 95, 101, 102, 118, 119
Oldfield, J. 167, 178
Oliverio, V. T. 17, 25
Olsen, N. J. 248, 263
Olson, S. 231, 236, 241, 244
Orencole, S. F. 260, 265
Ornstein, L. 142, 155
Oronsky, A. L. 7, 11, 212, 215, 217, 247–265
Osawa, H. 250, 251, 264
Osborn, M. J. 191, 206
Ota, K. 16, 25
Otter, G. M. 7, 11
Ötting, F. 145, 156, 231, 243
Owens, E. S. 13, 24

Packer, R. J. 82, 84, 95
Paigen, K. 233, 245
Palm, D. 64, 71
Panasci, L. 270, 276
Pancoast, T. 104, 119
Papadopoulos, E. 267, 276
Parada, L. F. 101, 102, 118
Parandoosh, Z. 97–121
Parks, R. E., Jr. 113, 120
Pastan, I. 65, 71, 72, 232, 244
Patil, S. D. 209, 216
Patterson, J. L. 114, 120
Patton, T. F. 82, 84, 95
Paul, J. 233, 245
Paul, W. 119
Paulik, E. 88, 91, 95, 101, 118
Paull, K. D. 75, 94, 101, 118
Pawelczak, K. 167, 170, 178, 179
Pawlak, K. 114, 120
Payment, C. 280, 285
Pearson, D. 100, 117
Pedersen-Lane, J. 181, 186
Penit, J. 64, 71
Pennington, K. 75, 76, 80, 87–91, 101, 119
Penziner, A. 267, 268, 273, 275
Periti, P. 280, 285
Perryman, S. M. 182, 187
Petersen, A. R. 162, 176
Peterson, L. B. 115, 121
Petrelli, N. 162, 177
Petrini, M. 232, 244
Peuch, C. L. 114, 121
Pfleiderer, W. 243
Phillips, J. O. 162, 176
Pickering, M. V. 101, 118
Pickett, W. C. 253, 254, 264
Pierce, J. V. 191, 206
Pillwein, K. 75, 94, 102, 119
Pincus, T. 248, 263
Pinter, C. D. 28, 35, 46
Piper, J. R. 5, 7, 10, 11, 13, 23, 24
Piťha, J. 219, 227
Pitirangon, P. 19, 25
Pitot, H. C. 162, 176
Pizzorno, G. 277–285
Plagemann, P. G. W. 64, 71

Plante, L. T. 191, 194, 206, 207
Plese, P. C. 201, 202, 207
Pleven, E. 189, 205
Plowman, J. 75, 94, 101, 118
Plunkett, W. 43, 46
Pogolotti, A. L. 182, 187
Polakis, P. G. 113, 120
Polisson, R. P. 247, 248, 263
Polk, J. R. 261, 265
Polland, A. L. 144, 156, 190–194, 205
Poore, G. A. 209, 216
Pope, R. M. 255, 264
Poplack, D. G. 65, 71
Portillo, R. M. 6, 7, 9, 11, 14, 21, 24, 26
Portlock, C. S. 231, 236, 241, 244
Poser, R. G. 237, 245
Potmesil, M. 267–276
Prajda, N. 75–77, 85, 87–94
Price, E. M. 6, 11, 13–26
Priest, D. G. 161, 174, 191, 197, 206, 211, 212, 214, 217
Probst, H. 231–245
Puchtler, I. 182, 187
Purich, D. L. 156

Qhachas, E. T. 5, 6, 10

Radacic, M. 165, 178
Radar, J. I. 231, 243
Radparvar, S. 190, 191, 206
Raghavan, D. 82, 84, 95
Rall, D. P. 13, 24, 253, 264
Randall, R. E. 182, 186
Randolph, J. R. 13, 24
Rao, K. N. 195, 207
Rapachietta, D. 27, 45
Rath, N. 248–250, 264
Ratnam, M. 13–26
Rau, R. 247, 263
Ravazzoni, C. 223, 228
Reading, J. C. 247, 248, 263
Rehder, M. C. 250, 261, 264
Reich, K. 27, 45
Reichard, P. 123, 124, 138, 171, 179
Reinsch, J. W. 150, 156, 202, 207
Revankar, G. R. 97–121
Rey, D. A. 123, 137
Reyes, P. 54, 60
Rhee, M. S. 7, 11, 211, 212, 215–217
Richter, J. 182, 187
Ridge, S. C. 248–250, 255, 264
Riehm, H. 232, 244
Rindler, M. J. 64, 65, 71
Riordon, J. R. 65, 71, 232, 244
Rivest, R. S. 231, 236, 241, 244
Riviere, Y. 114, 121
Rixon, R. A. 123, 137
Rizkalla, B. H. 115, 121
Robbie, M. A. 33, 46
Robbins, T. J. 102, 110, 119
Roberts, A. B. 88, 91, 95
Roberts, D. 162, 175, 231, 243
Roberts, G. C. K. 59, 175, 177, 232, 245
Roberts, J. D. 82, 84, 95
Robins, R. K. 75, 88, 91, 93–95, 97–121
Robinson, B. A. 163, 177
Robson, C. N. 267, 270, 275
Rodbard, D. 261, 265
Rode, W. 183, 184, 187, 191, 197, 206
Rodeman, K. 17, 19, 25
Rodenhuis, S. 278, 284
Roesler, W. J. 100, 118
Rollins-Smith, L. A. 115, 121
Ronison, I. B. 65, 71
Rosenberg, M. 182, 183, 187
Rosenblatt, D. S. 280, 285
Rosenheim, S. 219, 227
Rosenthal, W. 98, 117
Rosowsky, A. 7, 12, 148, 156, 164, 174, 178
Rossana, C. 182, 187
Rosso, R. 223, 228
Rothenberg, S. P. 7, 11, 12, 19–21, 25
Rotundo, R. 209–217
Rozencweig, M. 219, 227
Rubalcava, B. 97–121
Rubin, E. H. 123, 137
Rubin, E. M. 182, 184, 187
Rubin, R. C. 13, 24
Rusetti, F. W. 249, 264
Russell, A. S. 247, 262, 263, 265
Russell, F. A. 124, 138
Russell, I. J. 255, 264
Ruysschaert, J. M. 219, 227
Rzeszotarska, B. 170, 179

Sabourin, C. L. K. 123, 138
Sadasivan, E. 7, 11, 12, 19–21, 25
Sadee, W. 113, 114, 120, 162, 175, 176
Saier, M. H., Jr. 64, 65, 71
Sakai, K. 98, 100, 117
Sakanove, Y. 98, 100, 117
Sala, R. 223, 228
Sallon, S. E. 82, 84, 95
Sambrook, J. 233, 245
Sampson, D. 82, 84, 95
Sams, K. 14, 17, 25
Samuels, L. L. 13, 23
Samuelson, C. O. 247, 248, 263
Sani, B. P. 191, 197, 206

Santi, D. V. 47, 50, 51, 53, 57, 59, 141, 154, 155, 181, 182, 186, 187, 189, 205
Santi, L. 223, 228
Sanwal, B. D. 101, 118
Sartorelli, A. C. 24, 88, 91, 95, 219, 227
Sato, A. 123, 124, 128, 137, 138
Sato, C. 16, 25
Sauer, H. 237, 245
Saunders, G. F. 234, 245
Saunders, P. P. 75, 94, 102, 114, 119
Savage, N. 260, 265
Scanlon, J. 183, 187, 191, 206
Scavone, S. V. 28, 35, 46
Schalhorn, A. 227, 245
Schaller, J. G. 257, 260, 265
Scharschmidt, B. F. 16, 25
Schein, P. S. 162, 175
Schilsky, R. L. 13, 23
Schimke, R. T. 8, 12, 231, 235, 236, 241, 244
Schlichter, D. 100, 117
Schmid, F. A. 7, 11, 281, 285
Schmidt, H. 231–245
Schneller, S. W. 123, 124, 137
Schoenfeld, D. 27, 45
Schornagel, J. H. 234, 236, 241, 244
Schroeder, J. M. 254, 264
Schuetz, J. D. 6, 8, 11
Schultz, G. 98, 117
Schuman, D. A. 100, 118
Schwab, J. H. 248, 254, 263
Schwert, G. W. 146, 156
Scott, D. G. 247, 263
Scott, J. M. 191, 197, 206
Scott, P. 162, 176
Scouten, W. H. 197, 207
Scurr, R. D. 237, 244
Seabright, M. 234, 245
Sebolt, J. S. 28, 35, 46
Sedgwick, A. D. 249, 264
Segal, A. M. 247, 263
Seiler, H. 144, 156
Seno, T. 123, 138, 181, 186
Sessa, C. 163, 178
Shader, R. I. 84, 95
Sharma, B. S. 105, 119
Sharma, R. K. 157, 156
Sharp, J. T. 248, 263
Sheetz, R. J. 247, 263
Shen, T. 270, 276
Sherman, M. L. 113, 120
Shibahara, S. 100, 117
Shih, C. 5, 10, 209, 216
Shimatake, H. 182, 183, 187
Shimizu, K. 181, 186
Shimizu, S. 16, 25
Sholar, P. W. 3, 10
Siddik, Z. H. 163, 165, 177, 178
Sidwell, R. W. 101, 118
Siegler, R. 82, 84, 95
Sigal, N. H. 115, 121
Sikes, D. H. 261, 265
Sikora, E. 163, 164, 170, 177–179, 209, 216
Silber, R. 231, 243, 267–276
Silks, L. A. 189, 205
Silkworth, J. 248, 263
Simmonds, A. J. 170, 178
Simmonds, H. A. 177, 179
Simon, L. N. 100, 118
Singer, T. P. 205
Sirotnak, F. M. 5–8, 10–13, 17, 18, 23–25, 62, 71, 162, 175, 186, 210, 217, 231, 235, 237, 243, 245, 281, 285
Skalski, V. 270, 276
Slamon, D. J. 65, 71
Slate, D. L. 231, 235, 236, 243
Slavík, K. 191,197, 206
Slavíková, V. 191, 197, 206
Sloboda, A. E. 248–250, 263
Slocum, H. K. 232, 244
Slomiang, B. L. 19, 25
Smee, D. F. 97–121
Smigel, M. D. 97, 113, 117
Smith, C. D. 105, 108, 119
Smith, I. E. 163, 177
Smith, P. L. 14, 17, 24, 25
Smithers, M. J. 47, 59, 165, 178
Smithson, W. A. 82, 84, 95
Snyderman, R. 105, 108, 113, 119, 120
Sobrero, A. 8, 12
Sokoloski, J. A. 88, 91, 95
Sommer, H. S. 182, 187
Sonenberg, M. 13, 23
Soparkar, S. 98, 115–117
Spector, R. 13, 14, 24
Spengler, R. A. 232, 244
Spitzer, N. 64, 65, 71
Spoelstra, E. 219, 227
Sporn, M. B. 88, 91, 95
Spriggs, D. R. 113, 120
Springer, C. S. Jr. 220, 222, 228
Srimatkandada, S. 277, 284
Srivastava, P. C. 75, 93, 94, 101, 104, 118, 119
Stahl, R. L. 267, 276
Starnes, M. C. 170, 179
Stathopoulos, G. 177
Staubus, A. E. 114, 120
Steele, T. A. 109, 120
Steeper, J. R. 124, 138
Stein, S. 19, 25
Steinkampf, R. W. 27, 45, 65, 72
Steinson, L. A. 82, 84, 95

Steuart, C. D. 124, 138
Stewart, D. J. 82, 84, 95
Stewart, J. A. 82, 84, 95
Stocker, A. 47, 59, 165, 178
Stoeckler, J. D. 113, 120
Stopp-Pantot, G. 237, 245
Storms, R. K. 182, 187
Streeter, D. G. 101, 118
Stroud, R. M. 50, 51, 59, 141, 154, 155
Stryer, L. 97, 117
Stuhmiller, L. M. 141–157
Suarez, C. R. 253, 254, 264
Sugar, J. 88, 91, 95, 101, 118
Suleimann, S. A. 14, 24
Suresh, M. R. 5, 6, 10, 61, 68, 70
Susten, S. S. 14, 18, 25
Sutherland, R. M. 27, 33, 45, 46
Svendsen, I. B. 6, 11, 19–21, 25
Sylvester, R. F. 277, 284
Szelenyi, J. 88, 91, 95, 101, 118

Tagger, A. Y. 136, 139
Tagliaferri, P. 100, 101, 118
Takahashi,M. 27, 45
Takai, Y. 113, 120
Takano, M. 219, 222, 228
Takeishi, K. 181, 186
Talal, N. 255, 264
Talbert, P. T. 191, 206
Tanaka, T. 182, 187
Tanaka, Y. 98, 100, 117
Tang, A. 128, 138
Tapiovaara, H. 101, 104, 118
Tattersall, M. H. N. 162, 175
Taylor, E. C. 5, 10, 141, 155, 209, 216, 261, 265
Taylor, G. A. 161–179
Taylor, G. R. 182, 187
Taylor, K. W. 64, 71
Taylor, M. A. 165, 178
Teicher, B. A. 270, 276
Temple, C., Jr. 191, 197, 206
Terres-Garcia, S. J. 270, 276
Teufel, T. 234, 236, 245
Thelander, L. 123, 129, 136–139
Thiebaut, F. 65, 71
Thompson, L. H. 232, 244
Thompson, R. N. 247, 263
Thorndike, J. 5, 10, 209, 216,
Thorner, J. 190, 197, 206
Thornton, T. J. 165, 178
Timmers, R. J. M. 219, 227
Tishler, M. 260, 262, 273, 275, 276
Tökès, Z. A. 219, 227
Tolman, R. L. 115, 121
Toltzis, P. 114, 120
Tons, G. I. 19, 25
Tormey, D. C. 82, 84, 95
Tortora, G. 100, 101, 118
Traganos, F. 267, 268, 273, 275, 276
Traggis, D. 231, 232, 235, 244
Trautivein, W. 98, 117
Trave, F. 162, 177
Trent, J. 65, 71
Trent, J. M. 231, 236, 241, 244
Trentham, D. E. 247, 248, 257, 263
Tricot, G. J. 75–85, 87–92, 94, 101, 119
Tripp, E. 231, 244
Tritton, T. R. 219, 227
Trosko, J. E. 123, 138
Trump, D. L. 82, 84, 95
Tseng, B. Y. 162, 176
Tsuda, K. 182, 187
Tsuda, T. 113, 120
Tsuji, J. M. 6, 8, 11, 61–64, 70, 71, 153, 156
Tsukamoto, I. 190, 296
Tsuruo, T. 65, 71
Turner, M. K. 123, 137
Tutsch, K. D. 82, 84, 95
Tzeng, D. Y. 76, 94

Uchiyama, F. 223, 228
Ueda, K. 65, 71
Ueno, N. 219, 228
Uhing, R. J. 113, 120
Ullman, B. 123, 138, 162, 176
Utley, C. 6, 9, 11, 14, 16, 20, 24

Vacek, P. M. 262, 265
Valeriote, F. A. 27, 33, 45, 91, 95
Van Cott, A. C. 75, 94
Van der Neut, R. 219, 227
Van Hoff, D. D. 28, 35, 46, 82, 84, 95
Van Putten, L. 27, 33, 45
Van't Riet, B. 129, 139
Vandenbark, G. R. 100, 118
Vandenbranden, M. 219, 227
Vanentwerp, D. 27, 45
VanHorn, K. C. 6, 9, 11, 14, 16, 20, 24
Vanin, F. F. 182, 187
Vasey, F. B. 261, 265
Vasquez, T. 39, 46
Verghese, M. W. 105, 108, 119
Verkleij, A. J. 219, 227
Verma, R. S. 6, 8, 11
Vest, S. 163, 177
Via, C. S. 247, 263
Vitols, K. S. 5, 6, 10, 61, 68, 70, 260, 265

Votruba, I. 54, 60
Vuchich, M.-J. 280, 285

Wagner, C. 13, 24
Wahba, A. J. 145, 156
Wahl, S. M. 257, 265
Wakelam, M. J. O. 101, 118
Waldrop, A. A. 147, 156
Wallace, M. A. 98, 117
Wallen, C. A. 27, 45
Walsdorfer, V. 254, 264
Wampler, G. L. 129, 139
Ward, D. C. 146, 153, 156
Ward, J. R. 247, 248, 263
Warren, R. D. 13, 23
Washtien, W. L. 181, 186
Watts, C. 247, 263
Waxman, S. 6, 7, 9, 11
Webber, S. 141–157, 261, 265
Weber, G. 29, 46, 75–95, 101, 102, 107, 114, 118, 119
Webster, H. K. 102, 105, 119
Weckbecker, A. 123, 138
Weckbecker, G. 123, 138
Weigle, W. O. 115, 121
Weimer, G. 64, 71
Weinberg, R. A. 101, 102, 118
Weinblatt, M. E. 247, 248, 257, 263
Weiner, S. R. 247, 248, 263
Weinstein, I. B. 98, 117
Weiss, E. R. 98, 115–117
Weissman, B. N. 248, 257, 263
Welles, W. 248, 263, 264
Wellstein, A. 64, 71
Werkheiser, W. C. 162, 176
West, S. G. 247, 248, 263
Westin, E. H. 6, 8, 11
Wettergren, Y. 232, 244
Whang-Peng, J. 232, 244
Wheeler, M. R. 145, 151, 152, 156
White, C. S. 247, 263
White, J. C. 13, 24
Whitehead, B. M. 10
Whitehead, V. M. 24, 178, 179, 217, 264, 280, 285
Whiteley, J. M. 141–157, 190, 206, 260, 261, 265
Whitfield, J. F. 123
Whitmore, G. F. 162, 175, 261, 265
Wicker, L. S. 115, 121
Wicks, W. D. 100, 117
Wilchek, M. 205, 207
Wilder, R. L. 247, 263
Wilke, W. S. 247, 248, 257, 263
Wilkens, R. F. 247, 248, 263
Wilkinson, D. S. 162, 176
Willems, Y. 163, 178
Williams, H. J. 247, 248, 263
Williams, S. D. 65, 72
Williams, S. R. 123, 137
Willingham, M. C. 65, 72
Willis, R. C. 97–121
Willoughby, D. A. 249, 264
Wilmanns, W. 237, 243, 245
Wilson, G. A. 182, 184, 187
Wilson, W. R. 34, 46
Wilson, Y. A. 114, 120
Wiltshaw, E. 163, 177
Winefordner, J. D. 207
Winer, A. D. 146, 156
Wintrobe, M. M. 277, 284
Wishnia, A. 220, 222, 228
Withers, H. R. 45
Witkowski, J. T. 101, 118
Wodinsky, I. 231, 243
Wohlrab, F. 190, 206
Wojcikiewicz, R. J. W. 98, 117
Wolfard, T. S. 28, 35, 36, 46
Wolff, J. A. 277, 284
Wolfman, A. 101, 118
Woods, R. 82, 84, 95
Woon, C. W. 98, 115–117
Worku, Y. 110, 120
Wormsted, M. A. 123, 138
Wright, D. G. 88, 91, 95, 102, 105, 113, 119, 120
Wright, J. A. 123, 136, 138, 139
Wright, L. D. 206
Wu, H.-Y. 273, 276
Wu, Y. 192, 207

Yabushita, H. 219, 228
Yagi, K. 219–228
Yagoda, A. 13, 23
Yalowich, J. C. 278, 284
Yamada, Y. 75–85, 87–90, 94, 102, 107, 114, 119
Yamaji, Y. 75–78, 80, 85, 87–92, 94, 102, 119
Yamamura, H. 18, 100, 117
Yamanaka, N. 16, 25
Yamashita, T. 113, 120
Yang, C. H. 248, 254, 263
Yang, C.-H. 6, 11, 18, 25
Yarboro, C. 247, 248, 263
Yaron, M. 260, 292, 265
Yates, B. B. 182, 187
Yeh, G. C. 3, 5, 10, 210, 217
Yip, C. C. 97, 117
Youdale, T. 123, 137
Young, F. E. 182, 184, 187
Young, J. A. 82, 84, 95

Young, R. C. 162, 175
Yu, A. L. 44, 46
Yu, C.-S. 148, 156
Yu, J. 44, 46
Yu, M. 112, 120

Zabriskie, J. B. 249, 250, 255, 264
Zakrzewski, S. F. 162, 176, 177
Zapf, J. W. 189–207
Zeveley, E. M. 5, 10, 16–18, 25, 61–63, 65, 70, 71, 147, 156
Zhen, W. 75–77, 85, 87–92
Ziff, M. 255, 257, 264
Zimm, S. 82, 84, 95
Zubrod, C. G. 39, 46
Zucchetti, M. 163, 178
Zwelling, L. A. 75, 94

SUBJECT INDEX

β-Actin cDNA
  expression in human leukemia 240
  hybridization probe 234
Actinomycin D
  on RNA synthesis in CCRF lines 239, 240
  selection of resistant CCRF line 238
  treatment and multidrug resistance 232
Acute leukemias *see* Human leukemia
Adenosine kinase (EC 2.7.1.20)
    phosphorylation of tiazofurin 102
Adenylate cyclase (EC 4.6.1.1)
  activation by G protein 97, 100, 108
  in gene expression 99
ADP reductase in L1210 WT and HU-7 extracts 132
Adriamycin (ADM, doxorubicin)
  binding with sulfatide-containing liposomes 219–223
    electrostatic interaction 222
  –cardiolipin complex 219
  cardiotoxicity 219
  chemotherapy 219–227
    comparison with NSC 366140 43
    computer simulation studies 36
  on CLL lymphocytes 274
  on P and Q CHO cells 33
  on RNA synthesis in CCRF lines 239, 240
  on topoisomerase II 273
  resistance of CCL lymphocytes 272–275
  selection of resistant CCRF line 238
  tissue distribution, liposome entrapment on 223
    blood, time course 224
    heart, time course 224
    tumor, time course 225
  treatment and multidrug resistance 232
Alanine transaminase increase, antifolate toxicities and 169
Alkylating agents
  on quiescent cells 32, 33, 34
  toxicity, sulfhydryl groups on 270
Allopurinol
  in tiazofurin treatment protocol 78, 85
  on GPRT 85, 90, 93
  on GTP biosynthesis 78
  on guanine salvage 76
  on plasma hypoxanthine 76, 78, 85–87, 93
  on uric acid production 85–87
5-(3′-Amino)allyl deoxyuridine monophosphate
  ^{1}H NMR resonance shifts 149
  preparation 143, 147, 153
N^{α}-(4-Amino-deoxy-10-methylpteroyl) -N^{ϵ}-(4-azidosalicylyl)-L-lysine
  ^{125}I labeled 14
  inhibition of influx by MTX 18
  photoaffinity labeling studies 14–16
  uptake by L1210 cells 14, 18
5-Amino-4-imidazolecarboxamide ribotide (AICAR) transformylase (EC 2.1.2.3)
  inhibition by DHF 3
  inhibition by MTX 210
  inhibition by MTX-polyglutamates 5, 161, 261
  target for folate-dependent enzyme inhibition 4, 210
4-Amino-10-methyl folate *see* Methotrexate
Aminopterin
  analogs compared to MTX 7
  suppression of inflammation in adjuvant arthritis 250
4-Amino-8(β-D-ribofuranosylamino)-pyrimido[5,4-d]pyrimidine5′-phosphate (APP-MP)
  formula 34
  on P and Q CHO cells 33, 35
  on RNTP pools 35
cAMP
  efflux from mammalian cells 64, 65
  regulation in cellular differentiation 101
  regulation, lymphocyte activation and 105
Anion detoxification 61–70
  cholate efflux 66–70
  efflux pump, substrates 69
  folate and urate efflux 68, 69
  general mechanism 66
Anthracyclines, improvement in therapeutic efficiency 274
Anticancer chemotherapy *see* Chemotherapy
Antifolates *see also* Individual compounds
  drug development 3–10
    lipid-soluble 7
    M-FBP and 7, 8
    transport and polyglutamation 5, 7
  in chemotherapy 161–174

inhibition of TS by MTX-AA-dUMP 141–155
transport defect in L1210/R81 cells 14, 18, 19
Antiviral activity of 7-thia-8-oxoguanosine in mice 111, 112
Aphidicolin on ribonucleotide reductase 123
Arthritis in rats *see* Rat arthritis

Bacillus subtilis TS active site region 182
Bacteriophage T4 TS
active site region 181
specific activity 184
His to Val mutation on 185
Bacteriophage ϕ3T (*B. subtilis*) TS
active site region 182
peptide sequence analysis 183, 184
valine residue 6 183, 184
amino end analysis 184, 185
gene 184
specific activity 184
B-cell activation
by 7-thia-8-oxoguanosine 105, 107, 115
G protein binding and 115
BCNU *see* Carmustine
N^6-Benzyl-cAMP
on K562 cells 100
structure 101
Bile acids efflux 69
Bilirubin efflux 69, 70
Bleomycin on P and Q CHO cells 33
Bromosulfothalein (BSP) inhibition
of cholate efflux 67, 68
of folate efflux 68
of MTX efflux 63, 68, 69
Burkitt's lymphoma
line Raji (ATCC CLL86)/MTX-6 resistant line 234, 235
DHFR gene amplification 235
topoisomerases in 273

Calcium ions (Ca^{2+}) as second messenger in transmembrane signals 107
Camptothecin
analogs as possible chemotherapeutic agents 275
on CLL lymphocytes 274
on DNA-topoisomerase I complex 273
Carbonyl cyanide *m*-chlorophenylhydrazone (CCCP) inhibition
of cholate efflux 67, 68
of MTX influx 64, 68
Carboxyfluorescin entrapment by liposome 220
Carboxypeptidase in TMTX treatment 284
Cardiolipin
–adriamycin complex 219
liposome ADM binding 219, 220
Carmustine (BCNU)
chemotherapy, computer simulation studies 36
Q cells and 41, 43, 44
with cytarabine 43, 44
on P and Q CHO cells 32, 33
CDP reductase in L1210 cell extracts
WT and ED2 133, 134
WT and HU-7 132
WT and Y-8 133
Cerebroside, liposome ADM binding 220
Chemiluminescence in
B cells 108
HL60 cells 102, 103
PEC 105, 106, 109
Chemotherapy
adriamycin 219–227
antifolate 3–10, 13–22
antiviral 114
computer simulation (ExChemo) 36–44
cell loss factor 39, 41
10-compartment model 37
cytokinetic 37, 38
inhibition kinetics 37, 38
pharmacokinetic 36, 37
Q cells on drug response 39–45
genetic expression and 97–117
MTX
multidrug resistance and 231–243
sensitivity and resistance 277–284
multidrug resistance and unidirectional efflux routes 65, 66, 70
of childhood malignancies 231–243
of CLL, chlorambucil and adriamycin resistance 267–275
quiescent (Q) cells and 27–45
tiazofurin 75–93
combination with retinoic acid 91
TS as target 141, 161–174, 189
Chinese hamster ovary (CHO) cells
chlorambucil resistant line, DNA binding of CLB 270
K1 line
culture 28
drug sensitivity of proliferating (P) and Q cells 30
adriamycin 33
APP-MP 33
bleomycin 33
CB3717 33
carmustine 32, 33
cisplatin 33
etoposide 33

5FU 33
NSC 366140 33, 34
NSC 377163 33, 34
relation to DNA and RNA synthesis 34, 35
6-thioguanine 32, 33
growth curve to quiescence 29
thymidine incorporation 30
uridine incorporation 30, 31
MTX resistant line 8
Chlorambucil (CLB)
in B cell disorders 272
on GSH content of lymphocytes 271
resistance prediction possibility 274
uptake
in CHO cells 270
in CLL cells 268, 269
DNA binding 269
metabolism and, *in vivo* 267, 268
8-Chloro-cAMP
chemotherapy 116
induced differentiation 116
on G protein regulation 105
on human cell lines 100
on K562 cells 100
on MCF-7 cells 101
on protein kinases 101
structure 101
Cholate
efflux inhibition by
BSP 67, 68, 70
CCCP 67, 68
diamide 67, 68
MTX 67, 68
probenicid 67, 68
prostaglandin A_1 67, 68
quinidine 67, 68
reserpine 67, 68
verapamil 67, 68
vincristine 67, 68
efflux measurement 62
uptake by L1210 cells 62, 66, 67
Cholera toxin
inhibition of GTPase activity 98
on HL60 cells 102, 103
on mouse PEC 109
Cholesterol content of ADM-trapping liposomes 219, 227
Cibacron blue agarose in TS purification 190
Cisplatin on P and Q CHO cells 33, 44
CM-Sephadex in TS purification 192–196
Conjugase *see* γ-Glutamyl hydrolase
Cytarabine (Ara-C, arabinosylcytosine)
chemotherapy, computer simulation studies 36
cytokinetic parameters and drug response 39–41
Q cells on 43
with carmustine 43, 44

DDMP *see* Metoprine
Deoxyadenosine
inhibition of L1210 cell growth
on ED2 line 127, 130
on HU-7 line 127, 128
on Y-8 line 127, 129
synergism with HU 125, 126
on cytidine metabolism 135
Deoxyguanosine inhibition of L1210 cell growth
on ED2 line 127, 130
on HU-7 line 127, 128
on Y-8 line 127, 129
synergism with IMPY 125, 126
2′-Deoxyuridine 5′-phosphate *see* dUMP
2-Desamino-2-methoxy-N^{10}-propargyl-5,8-dideazafolic acid (CB3828)
as FPGS substrate 171, 174
structure 163
TS inhibition in whole cells 171–173
2-Desamino-2-methyl-N^{10}-propargyl-5,8,dideazafolic acid (DMPDDF, CB3819)
as FPGS substrate 171, 174
plasma clearance 169
structure 163
toxicities in mouse 169
TS inhibition 209
in whole cells 171–173
polyglutamates on 170
2-Desamino-N^{10}-propargyl-5,8-dideazafolic acid (CB3804)
aqueous solubility 166
as FPGS substrate 171, 174
cytotoxicities 166
plasma clearance 169
structure 163
toxicities in mouse 169
TS inhibition 166
in whole cells 171–173
polyglutamates on 170
Diacylglycerol (DAG)
selenazofurin on 104, 113
tiazofurin on 104, 113
Diamide inhibition
of cholate efflux 67, 68
of MTX efflux 67, 68
Dibromodulcitol synergism with tiazofurin 91
Dicetyl phosphate liposome, ADM binding 219, 220

5,8-Dideaza-10-propargylfolic acid (CB3717)
on P and Q CHO cells 33
5,10-Dideaza-5,6,7,8-tetrahydrofolate (DDATHF)
growth inhibition, folate levels on 215, 216
inhibition of GAR transformylase 209, 210, 261
on adjuvant arthritis 261
synergism with TMTX 7
Differentiation induced by tiazofurin 87–89, 102, 113, 116
Difluorodeoxycytidine, computer simulation chemotherapy study 42, 43
Dihydrofolate
in folate metabolism scheme 210
in MTX-treated cells 210
inhibition of AICAR T'ase 3
inhibition of TS 3
salvage impairment by reductase inhibitors 215
Dihydrofolate reductase (DHFR, EC 1.5.1.3)
as possible target in rheumatoid arthritis therapy 261
assay 145
binding of folate-like molecules 55
cellular characteristics for MTX cytotoxicity 278
gene
amplification 231, 242
in clinical treatment 236, 241, 242
in Raji/MTX-6 cells 235
in TE-85/MTX-7 cells 236
copies in MTX-resistant cells 235
human, location on chromosome 5 235, 236
hybridization probe 234
homology with IL-1β 259
in folate metabolism scheme 210
inhibition by
CB3717 166
CB3717 analog polyglutamates 170
CB3804 166, 167
folic acid analogs 162, 163
MTX 3, 150
MTX-AA-dUMP 150, 154
inhibition, folate depletion on 209–216
inhibition in cancer cells 13
inhibition, *in situ* TS assay for 278
inhibitor requirements 4
MTX resistance and 231
overproduction in L1210/R81 cells 14, 18
overproduction in MTX-resistant cells 235
2,3-Dihydro-1H-imidazo(1,2-b)pyrazole (IMPY)
inhibition of L1210 cell growth
ED2 line 127, 130
HU-7 line 127, 128
Y-8 line 127, 129
synergism with deoxyguanosine 125, 126
on cytidine metabolism 135
DNA binding of chlorambucil 269
in CHO resistant line 270
DNA polymerase (EC 2.7.7.7) substrate production pathway 123, 124
DNA topoisomerase I (EC 5.99.1.2)
content of various cell types 273
–DNA complex, camptothecin stabilization 273
inhibitors on CLL lymphocytes 274, 275
DNA topoisomerase II (EC 5.99.1.3)
content of various cell types 273
–DNA complex, stabilization by drugs 273
in ADR cytotoxicity 273
inhibitors of 33, 44
inhibitors on CLL lymphocytes 274
Doxorubicin *see* Adriamycin

10-EDAM (antifolate)
cytotoxicity versus TS activity 281, 283
on rat sarcoma cells 281, 282
structure 282
Enzyme-pattern-targeted chemotherapy
allopurinol 78, 79, 85–87
tiazofurin 78–80, 84, 85, 87
Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) inhibition of adenosine deaminase 125–128, 135
Escherichia coli TS
active site region 181
gene 183
isolation from 49
specific activity 184
Etoposide on P and Q CHO cells 33
ExChemo mathematical model of chemotherapy 36–44
carmustine in 41, 43
cytarabine in 39–41, 43
cytokinetic model 38
difluorodeoxycytidine in 42, 43
major components 37
synergism predictions 44

2-Fluorodeoxyadenosine on resistant L1210 cell lines 131, 136

5-Fluorodeoxyuridine 5′-monophosphate (FdUMP)
binding to TS 50, 53, 59
in TS purification 190, 200
inhibition of TS 162, 182
structure 48
ternary complex with TS and methylene tetrahydrofolate 150, 201, 202, 204
ternary complex with TS and PDDF 47–59
location in 50, 54, 57
5-Fluorouracil (5FU)
chemotherapy limitations 161, 162
loci of action 162
on P and Q CHO cells 33
toxicity 162
Folate
accumulation in H35 cells 211
binding protein
from human placenta 16, 19, 20
from L1210 cells 18, 19, 22
relation of membrane to cytosolic 18–22
sources of membrane 5, 6
cofactors 3
dependent enzymes as chemotherapy targets 4
depletion by metoprine 211–215
efflux routes in L1210 cells 68
in TS purification 191
levels, cellular response to antifolates 215, 216
metabolism scheme and inhibitors 210
on TS–FdUMP binding 53
reduction in cultured cells 214, 215
transport
in L1210 cells 17
model for 19
in neoplastic cells 13
proteins 14
system, cell folate levels and 211
Folate derivatives *see also* Dihydrofolate
10-formyl DHF inhibition of TS 3
5-formyl tetrahydrofolate uptake
into L1210 cells 17, 19
system 13, 19
10-formyl tetrahydrofolate
cofactor in purine biosynthesis 4, 5
MTX on 3
5-methyl tetrahydrofolate
folate binding protein on 6
uptake into L1210 cells 17, 19
uptake system 13, 19
5-10-methylene tetrahydrofolate, MTX on 3
Folylpolyglutamate inhibition of TS 183
Folylpolyglutamate synthetase (FPGS, EC 6.3.2.17)
CB3717 and analogs as substrates 170, 171, 174
cell folate levels and 211
in MTX sensitivity of cells 280
MTX affinity in CCRF-CEM cells 280, 283
10-Formylfolate-aminohexyl-Sepharose in TS purification 191, 193, 197, 198
5-Formyltetrahydrofolate (leucovorin, LV) rescue
in MTX therapy 231, 236
in vitro studies 237
in TMTX therapy 284

Gene
expression
protein kinase C in 98
role of G proteins 113
signal transduction pathways 99
mdr1
amplification and expression in resistant CCRF lines 238, 240, 243
expression under clinical conditions 240–243
hybridization probe 234
overexpression in multidrug resistance 232, 238, 242, 243
γ-Glutamyl hydrolase (conjugase, EC 3.4.22.12)
MTX on 215
Glutathione
concentration in CLL lymphocytes 271
on alkylating agent toxicity 270
oxidized, efflux 69, 70
Glycineamide-ribonucleotide transformylase (GAR T'ase, EC 2.1.2.2)
inhibition by DDATHF 209, 210, 261
inhibition by MTX polyglutamates 5
target for folate-dependent enzyme inhibition 4
Glycoprotein p170, anion efflux and 65, 70
GMP-PNP (GTP analog) Ca^{2+} mobilization 107, 108
GTP
biosynthesis
de novo, tiazofurin on 78, 85, 87, 93
salvage pathway, allopurinol on 78, 85, 86, 93
concentration in blast cells, tiazofurin on 87, 88
GTPase
activity of G protein 97
inhibition by cholera toxin 98
selenazofurin on 104

tiazofurin on 104
Guanine nucleotide binding proteins (G proteins)
activation by guanosine analogs 107, 108
activation, nucleoside and nucleotide regulation 113, 114
binding of 7-thia-8-oxoguanosine 108
Ca^{2+} second messenger 107
cholera toxin on 102
classification 97
guanine nucleosides on 114–116
heteronuclear structure 97
immune response receptors and 105
in gene expression 99, 116, 117
in phospholipase C activation 98
selenazofurin on 104
α subunit, GTPase activity 97
tiazofurin on 102, 104, 113
transmembrane signalling 105–109
Guanine phosphoribosyltransferase (GPRT, EC 2.4.2.8)
activity in treated leukemic patients 90
inhibition by hypoxanthine 85, 93
Guanosine analogs
chemotherapy 116
on immune response 114–116
phosphorylation of 110, 111
7-thia-8-oxo
antiviral activity 111, 112
B cell activation 105, 107, 115
binding to G protein 108, 114
compared with deoxy analog 106, 107
interferon induction 105, 108–110
macrophage stimulation 105
natural killer cell stimulation 105, 109
M-FBP probe 9
MTX on 153
MTX/6 resistant line 234, 235
MTX-AA-dUMP on 153
multidrug resistant lines from 237
CCRF ACTD400 238–240
CCRF ADR1000 238
CCRF VCR1000 238
lymphoblastoid cell line RPMI1788 (ATCC CCL156) 232
lymphoblastoid cell line WI-L2
CB3717 cytotoxicity 166
CB3804 cytotoxicity 166
lymphocytes (normal)
GSH content 271
CLB on 271, 272
topoisomerase II absence 273, 274
lymphomas (*see also* Burkitt's lymphoma)
topoisomerases in 273
mammary carcinoma ZR75 cells, M-FBP probe 9
mammary tumor lines, 8-chloro-cAMP on 100, 101
neuroblastoma, mrd1 gene expression 241
osteosarcoma
cell line MG-63 (ATCC CRL 14271)/MTX-7 resistant 235
DHFR gene amplification 236
cell line SAOS-2/MTX-7 resistant 235
LV rescue 237
cell line TE-85/MTX-7 resistant 235
DHFR gene amplification 236
LV rescue 237
high dose MTX treatment 231, 236
placenta folate-binding protein 19, 20
amino acid sequences 21
homologies of peptides 20
relation to L1210 cell protein 19
reticulocytes M-FBP from 6
soft-tissue sarcoma
MTX resistance 281
TMTX on 284
T-cells C184 phosphotransferase activity 110
TS
active site region 181
specific activity 184
on Ca^{2+} 107, 108
phagocytosis induction 108–111
phosphorylation of 109–111
structure 106
superoxide anion generation by 105

HAG-IQ *see* 1-Isoquinolylmethylene-N-hydroxy-N′-aminoguanidine tosylate
Herpesvirus ateles TS active site region 182
Herpesvirus saimiri TS active site region 182
HIV genome, G protein and 114
Human
carcinomas, refractoriness to chemotherapy 27, 44
colon carcinoma HCT-8 cells
cell loss factor 30
culture 28
growth curve 30, 31
epidermoid carcinoma
cell lines
polyglutamate formation 280, 281
MTX sensitivities 280
KB cells, folate binding proteins 19
amino acid sequences 21, 22
homologies 20
M-FBP from 6, 9
MTX sensitivity 280

erythroleukemia K-562 cells
  N^6-benzyl cAMP on 100
  8-chloro-cAMP on 100
  tiazofurin induced differentiation in 88, 101
  tiazofurin induced down regulation of c-Ki-*ras* oncogene 91, 93
HCT-8 cells TMTX efflux 8
HeLa cells topoisomerase II content 274
leukemias
  ALL
    blast cells
      MTX polyglutamate formation 278–280
      retention of MTX 278
      sensitivity to folate antagonists 278
    tiazofurin treatment 80–85
  AML
    blast cells
      absence of MTX polyglutamylation 278–280
      sensitivity to folate antagonists 278
    resistance to chemotherapy 277
    tiazofurin treatment 80–85, 90, 101, 280
  CLL drug resistance 267–275
    lymphocytes
      adriamycin resistance 272–275
        topoisomerase II absence 273, 274
      GSH concentrations 271
        B cell instability 271
        CLB on 271, 272
      uptake of chlorambucil
        DNA binding 268
        HPLC and radioassay comparison 268, 269
  HL60 cells
    culture 76
    hypoxanthine on guanylates 77, 85, 86
    retinoic acid on 77, 91
    tiazofurin–retinoic acid synergism 91–93
    tiazofurin treatment
      chemiluminescence, phorbol ester stimulated 102, 103
      induced differentiation 77, 91, 92, 102, 113
      on DAG levels 113
  IMPDH activity in 75, 90
  mdr1 gene expression in 238, 240, 241
  tiazofurin chemotherapy 75–93
    allopurinol in 78, 85, 93
    clinical rationale 90
    critical issues in 76
    TAD from 90
    treatment protocol 78, 92
  topoisomerases in 273
  TS, dUMP binding to 54
lung carcinoma LX-1,8-chloro-cAMP on 100
lymphoblastoid cell line CCRF-CEM (ATCC CCL119)
  culture 146
N-Hydroxysuccinimide-MTX
  inhibition of folate efflux 68
  inhibition of MTX efflux 63
Hydroxyurea (HU)
  inhibition of L1210 cell growth
    on ED2 line 127, 130
    on HU-7 line 127, 128
    on Y-8 line 127, 129
    synergism with deoxyadenosine 125, 126
  on cytidine metabolism 135
  on ribonucleotide reductase non-heme iron subunit 128–131
Hypoxanthine
  allopurinol on 78, 85–88, 93
  in human plasma 85–87
  in tiazofurin-treated human leukemia 78
  on guanine salvage 85, 86
Hypoxanthine-guanine phosphoribosyltransferase(HGPRT,EC 2.4.2.8), allopurinol on 85, 90, 93

Immune response
  G protein binding and 115
  guanosine nucleosides on 114–116
  selective modulation 105–109
IMP dehydrogenase (IMP DH, EC 1.1.1.205)
  as chemotherapy target 75
  in leukemia 75, 90
  TAD inhibition of 75, 85, 87, 102
  tiazofurin inhibition of 75, 78–80, 84, 87
IMPY *see* 2,3-Dihydro-1H-imidazo(1,2-b)pyrazole
Inosine analogs, phosphorylation of 110, 111
Inositol triphosphate in gene expression 98, 99, 105
α-Interferon induction by
  pyrimidinones 115
  7-thia-8-oxoguanosine 105, 108–112
Interleukin 1 (IL-1) in adjuvant arthritis 249, 257–259

Interleukin 2 (IL-2) synthesis, MTX on 249, 255, 257, 262
1-Isoquinolylmethylene-N-hydroxy-N′-aminoguanidine tosylate (HAG-IQ) on resistant L1210 cell lines 127, 131

Lactobacillus casei TS
active site region 181
C terminal 57
3D structure 51
purification from 189–205
dUMP binding 54
Leishmania major TS active site region 181
Leucovorin (LV) *see* 5-Formyltetrahydrofolate
Liposomes binding of adriamycin 219–227
cardiolipin 219, 220
cerebroside 220
dicetyl phosphate 219, 220
on ADM antitumor activity 225–227
on ADM tissue distribution 223–225
phosphatidylserine 219–223
sulfatide 219–222
5-Lipoxygenase (EC 1.13.11.12) inhibition 250

Macrophage activation
consequences of 105
stimulation by pyrimidines 115
stimulation by 7-thia-8-oxoguanosine 105
Metallothionein on alkylating agent toxicity 270
Methotrexate (MTX)
analogs, improved transport 7
binding, comparison with MTX-AA-dUMP 152
chemotherapy, computer simulation studies 36
chemotherapy limitations 161
cytotoxicity, cellular attributes required 278
cytotoxicity mechanism 3, 4
depletion of one-carbon tetrahydrofolate pools 161
efflux measurement 62
efflux mechanisms 5, 8
efflux routes in L1210 cells, inhibition 62–66, 68–70
by BSP 63, 68, 69
by CCCP 64, 68
by diamide 64, 68
by 1-methyl-3-isobutylxanthine 64, 68
by NHS-MTX 63
by probenecid 63, 68, 69
by prostaglandin A_1 64, 68, 70
by quinidine 65, 66
by reserpine 65, 66
by verapamil 65, 66
by vincristine 64, 69
effect of buffer conditions 63, 64
relation to detoxification in multidrug-resistant cells 66
^{1}H NMR resonance shifts 149
in adjuvant arthritis 248
leucovorin on 260
metabolism in spleen cells 250
on IL-1 synthesis 249, 257–259
on macrophage function 259
on neutrophil chemotaxis 249
on passive disease 250, 252, 253
polyglutamylation 260, 261
suppression of inflammation 250, 251, 260, 262
in rheumatoid arthritis 247–262
chemical follow-up evaluations 248
inhibition of neutrophil chemotaxis 254
low dose oral Rheumatrex 247
treatment cessation and 254
in streptococcal cell wall-induced arthritis
on IL-2 synthesis 249, 255, 257
on inflammation 254
on joint destruction 255, 256
on mitogenesis 255, 257
on T-cell function 255, 257
influx and efflux systems in L1210 cells 61–70
inhibition of DHFR 150, 209, 210
inhibition of TS 141, 149
leucovorin rescue 162
M-FBP transport of 6
on CCRF-CEM cells 153
on folate levels 214
on γ-glutamyl hydrolase levels 215
on L1210 cells 153
on rat sarcoma cells 281, 282
photoaffinity analog 14–18
resistance, clinical, DHFR gene amplification 236
resistance determinants 8, 9, 162
resistance, DHFR and 231
resistance in childhood malignancies 231–243
resistance in differing cell types 277–284
distinction between acquired and intrinisic 284
resistant human cell lines 234
transport in 235
resistant L1210 cell line, TMTX on 7

sensitivity of AML and ALL blast cells 278
structure 282
toxicity 162
transport 13
treatment and leucovorin rescue 231
uptake into L1210 cells 17
model for 19
Methotrexate 5-aminoallyl 2′-deoxyuridine 5′-monophosphate (MTX-AA-dUMP) 141–155
bifunctionality 154
^{1}H NMR resonance shifts 149
^{3}H preparation 144
^{3}H uptake assay 146
inhibition of DHFR 150, 154
inhibition of TS 149
on CCRF-CEM cells 153
on L1210 cells 153
TS binding
absorbance difference spectra 152, 155
comparison with MTX 152
fluorescence quenching 150, 151, 155
gel electrophoresis 150
uptake limitations 154
Methotrexate polyglutamates
distribution in arthritic spleen cells 260, 261
formation in ALL blast cells 278–280
inhibition of AICAR transformylase 161, 261
inhibition of folate-dependent reactions 3–5
inhibition of TS 161, 261
in situ TS assay for 278
requirement for MTX cytotoxicity 278
4-Methyl-5-amino-1-formylisoquinolene thiosemicarbazone (MAIQ)
on resistant L1210 cell lines 127, 131
on ribonucleotide reductase non-heme iron subunit 128–131
5,10-Methylenetetrahydrofolate (CH_2-H_4PteGlu)
binding sequences in TS complex 56
in dTMP formation 141
in TS catalysis 47, 189
limitation in 5FU therapy 162
polyglutamate forms 54, 55
structure 48
TS-FdUMP ternary complex 201, 202
1-Methyl-3-isobutylxanthine (MIX) inhibition of
cholate efflux 67, 68
MTX efflux 64, 68
5-Methyltetrahydrofolate transport into cells 231
Metoprine (DDMP)
depletion of folates 211–215
growth inhibition, folate levels on 215, 216
inhibition of DHFR 209–211
on H35 cell growth 211, 212, 216
structure 211
Milk folate binding proteins 19
amino acid sequences 21
homologies 20
Monkey kidney epithelial cells MA104, M-FBP from 6
Mouse
CBA/CAJ 7-thia-8-oxoguanosine on 108–110
Glasgow osteosarcoma, tiazofurin on 101
graft versus host disease, MTX on 255
L1210 ascites tumor, TS inhibition 164, 165, 171, 172
CB3717 and analogs on 172, 173
L1210 cells
ADR on 273
anion detoxification by efflux pumps 61–70
cholate influx and efflux 62, 66–68
inhibition of 67, 68
culture 61, 62
folate binding protein 6
folate levels MTX on 214
folate and urate efflux routes 68, 69
lines resistant to ribonucleotide reductase inhibitors 123–137
ADP reductase in extracts 132
CDP reductase in extracts 132–134
comparison with wild-type 127–131
cross resistances, summary 136
cytidine metabolism, reductase inhibitors on 135
ED2 properties 127, 130–136
effector-binding subunit excess 134, 136
feedback control mechanisms and 136
four-drug combination 126
growth in HU, IMPY, deoxyadenosine or deoxyguanosine 127, 129
HAG-IQ on 131
HU-7 properties 127, 128, 131, 132, 134–136
MAIQ on 131
non-heme iron subunit excess 134, 136
selection of 124–127
Y-8 properties 127, 129, 131, 133, 135, 136

MTX cytotoxicity 153, 167
MTX efflux 5
inhibition 62–66, 68–70
MTX influx pathway, model 19
MTX resistant 8
line R81
photoaffinity labeling studies 14–19
transport defect 18
MTX sensitive line S, photoaffinity labeling studies 14–19
MTX with vinca alkaloids on 8
MTX-AA-dUMP cytotoxicity 153
phosphotransferase activity 110
selenazofurin on 104
tiazofurin on 104
topoisomerase II in 273, 274
TS inhibition by CB3717 and analogs 171–173
L1210 leukemia
selenazofurin on 104
tiazofurin on 104
Lewis lung carcinoma, tiazofurin on 101
model for neutrophil chemotaxis study 249, 252–254
nude, ovarian tumor bearing
ADM antitumor action, liposome entrapment on 225
on tumor growth and body weight 226
ADM tissue distribution, liposome entrapment on 223
time course in blood and heart 224
time course in tumor 225
P388 leukemia, tiazofurin on 104
peritoneal exudate cells (PEC)
phosphotransferase activity 110
stimulation by 7-thia-8-oxoguanosine 105–110
spleen cells Ca^{2+} mobilization in 108
TS active site region 182
Multidrug resistance
clinical correlation 241
efflux route and 65, 66, 70
in childhood malignancies 241, 242
P-glycoprotein and 232, 243
removal and retreatment on 238–243
resistant human cell lines 237, 238

NADPH oxidase (EC 1.11.1.2) in gene expression 99, 105
Natural killer cell stimulation by 7-thia-8-oxoguanosine 105
Neutrophil chemotaxis, MTX on 252, 253
Nucleoside regulation of G protein activation 113, 114
5′-Nucleotidase (EC 3.1.3.5)
phosphorylation of tiazofurin 102
Nucleotide
down regulation of G protein activation 113
ratios in L1210 cell extracts
selenazofurin on 104
tiazofurin on 104

myc Oncogene
down regulation
by retinoic acid 88, 91, 93
differentiation and 113
expression, protein kinases on 113
ras Oncogene
down regulation by tiazofurin 76, 88, 91, 93
GTPase activity 100, 114
Ovarian tumor (AMOC-I, endometrioid adenocarcinoma)
in nude mice, liposome-entrapped ADM on 223, 225, 226

P-glycoprotein
mRNA expression 240
role in multidrug resistance 232, 238, 241
Pentostatin (2′-deoxycoformycin)
on ATP pools 44
on resting lymphocyte 44
Pertussis toxin
G protein uncoupling 98
inhibition of chemiluminescence 108, 109
Phagocytosis induced by 7-thia-8-oxoguanosine 108–110
Phosphatidylcholine (PC) content of ADM-trapping liposomes 219, 221, 227
Phosphatidylinositol turnover
in gene expression 99, 105
protein kinase C activation and 98
Phosphatidylserine liposome, ADM binding 219, 222
Phosphocellulose in TS purification 190
Phospholipase C (EC 3.1.4.3)
G protein activation of 98, 105
phosphorylation 99, 101
Phosphorylation of nucleosides
phosphotransferase 109–111
ribavirin monophosphate donor 110
Phosphotransferase (EC 3.1.3.5)
activity in various cell lines 110
phosphorylation of guanosine and inosine analogs 111, 115

Polyacrylamide gel electrophoresis (PAGE)
native, separation of TS ternary complexes 201–203
Polyglutamation
importance in antifolate chemotherapy 171, 173
of CB3717 and analogs on TS and DHFR inhibition 170, 174
of MTX on enzyme inhibition 161
Polyglutamate substrates, TS binding sequence and 56, 57
PolyU in TS purification 190
Probenecid inhibition of
cAMP efflux 64
cholate efflux 67, 68
folate efflux 68
MTX efflux 63, 68, 69
10-Propargyl-5,8-dideazafolate (PDDF) *see also below*
binding to TS 50, 53, 54
quinazoline ring and 53–55, 59
folate levels and 214
growth inhibition, folate levels on 215, 216
on TS 209, 210
structure 48
ternary complex with TS and FdUMP 47–59
N^{10}-Propargyl-5,8-dideazafolic acid (CB3717)
analogs
amino acid variations 165
aryl and alkyl substituents in C^2 168, 169
cytotoxicity 168
TS inhibition 168
benzoyl ring modifications 165
N, O, S and Cl substituents in C^2 167
cytotoxicity 168
TS inhibition 168
N^{10} substituent variations 165
aqueous solubility 166
as FPGS substrate 171, 174
clinical activity 163
cytotoxicities 166
plasma clearance 169
structure 163
toxicities
human 163
kidney 163, 165, 169
liver 163, 169
mouse 169
TS inhibition 163, 166
in whole cells 171–173
polyglutamates on 170
Prostaglandin A_1
catabolites efflux 69, 70
inhibition of cAMP and MTX efflux 64, 68, 70
inhibition of cholate efflux 67, 68, 70
Protein, folate binding
amino acid sequence 16, 20, 21
antisera 17, 19
from human placenta
glycosylation 20, 22
labeling by MTX photoprobe analog 18
membrane-associated (M-FBP)
hybridization studies 9
properties 6
relation of cytosolic 18, 19, 21, 22
photoaffinity labeling 14–16, 18
Protein kinase A (cAMP-dependent protein kinase)
cellular transduction pathways and 112
in gene expression 99, 113, 116
phosphorylation of serine residues 98
stimulation by 8-chloro-cAMP 101
Protein kinase B (Ca^{2+}/calmodulin dependent protein kinase)
cellular transduction pathways and 112
in gene expression 99, 113, 116
Protein kinase C (PKC, EC 2.7.1.37)
cellular transduction pathways and 112
8-chloro-cAMP on 101
in cellular proliferation 98, 100
in gene expression 99, 105, 113, 116
inhibition by cholera toxin 102
selenazofurin on 104, 113
tiazofurin on 104, 113
ras Proteins reduction by 8-chloro-cAMP 100
PRPP synthetase inhibition by APP-MP 35
Purine
biosynthesis, inhibition of folate-dependent reactions 4
metabolism, tiazofurin and allopurinol on 87
Purine nucleoside phosphorylase (EC 2.4.2.1) gene hybridization probe 234
Pyraziloacridine NSC 366140
combination chemotherapy considerations 43
formula 34
on P and Q CHO cells 33
RNA synthesis 35, 45
Pyraziloacridine NSC 377163
formula 34
on P and Q CHO cells 33

Q-Sepharose chromatography in TS purification 192, 193, 196

Quiescent (Q) cells
chemotherapy and 27–45
combination 43, 44
simulated, effect on 36, 39–43, 45
culture system, description 29
G_0–G_1 transition and 27
nutrient-depleted monolayers and 28
reasons for drug effectiveness 45
Quinazoline-based antifolates 162, 163
structure-activity studies 165–174
Quinidine inhibition of
cholate efflux 67, 68, 70
MTX efflux 65, 66, 68, 70

Rat
arthritis, adjuvant induced 248
aminopterin on 250
intracellular MTX polyglutamate distribution in 260, 261
MTX on
I_α expression 258, 259
IL-1 synthesis 249, 257–259
inflammation 250, 251
macrophage function 258, 259
passive 250, 252, 253
arthritis, streptococcal cell wall induced 248
MTX on
IL-2 synthesis 249, 255, 257, 262
inflammation 254, 262
joint destruction 255, 256
mitogenesis 255, 257
T-cell function 255, 257
hepatoma 3924A cells 76
retinoic acid on 91
tiazofurin with dibromodulcitol on 91
hepatoma H35 cells
folate
accumulation 211
content of sublines 211, 212
depletion by metoprine 211–214, 216
growth inhibition by
antifolates, folate levels on 215, 216
metoprine 211, 212
synergism of TMTX and 5,10-dideazatetrahydrofolate on 7
sarcoma
10EDAM on 281–283
MTX on 281–283
TMTX on 281–283
Reserpine inhibition of
cholate efflux 67, 68, 70
MTX efflux 65, 66, 68, 70
Retinoic acid
down-regulation of *myc* oncogene 88, 91
on HL60 cell proliferation 91
synergism with tiazofurin 76, 91, 92
Rheumatoid arthritis, MTX treatment 247–262
clinical follow-up 248
mitogen response 255
neutrophil chemotaxis inhibition 254
toxicities 261, 262
treatment cessation and 254
Ribavirin, antiviral action 114
Ribonucleoside triphosphate pools
APP-MP on 35
pentostatin on 44
Ribonucleotide reductase (EC 1.17.4.1)
assays 124
critical properties of 123
in DNA replication 123, 124
inhibition
effects on L1210 cell lines 127–130
HAG-IQ 127, 128
MAIQ 127–129
inhibitors
on wild-type and resistant cells, cytidine metabolism and 135
specificity 136
properties in cell-free extracts from wild-type and resistant lines 130–134
subunit levels in resistant cells 134
subunits and inhibitors 123, 126

Saccharomyces cerevisiae TS active site region 182
Selenazofurin
chemotherapy 116
induced differentiation 116
on L1210 cells 104
on PKC 104, 113
structure 101
Sulfatide-containing liposomes, binding of adriamycin 219–227
agarose gel electrophoresis 220
efficiency of 220
on ADM antitumor activity 225–227
on ADM tissue distribution 223–225
Scatchard plots 221, 222
Superoxide anion generation
in HL60 cells 102
in peritoneal exudate cells 105, 108–110

Tetradecanoylphorbol acetate (TPA) stimulation of superoxide anion in HL60 cells 102, 103
Tetrahydrofolate in folate metabolism scheme 210

TAD (thiazole-4-carboxamide adenine dinucleotide)
from tiazofurin 89
in human leukemic cells 90
inhibition of IMPDH 75, 102
6-Thioguanine on P and Q CHO cells 32, 33
Thymidylate synthase (TS, EC 2.1.1.45)
active site regions
amino acid homology 181, 182
cysteine
protection 201, 205
significance 182
to arginine mutagenesis 182
to serine mutagenesis 182
histidine to valine mutagenesis 185
mutation on activity 182, 185, 186
sequence analysis 183, 184
activity versus cytotoxicity in antifolate assays 281, 283
assay in whole cells 164, 278
folate and nucleotide binding sites 141
immunodiffusion analysis 184
in one-carbon metabolism 141
inhibition by
CB3717 163, 171–173
CB3717 analogs 168, 171–173
CB3717 analogs polyglutamates 170
DHF 3
5FdUMP 150, 151, 162
MTX 150, 210
MTX-AA-dUMP 141–155
MTX polyglutamates 161, 261
PDDF 209, 210
inhibitor development 141
mechanism of action 141
MTX-AA-dUMP interaction
absorbance difference spectra 152
fluorescence quenching 150, 151, 155
gel electrophoresis 150
MW of dimer 189
MW of subunit 184
purification 183
purification from *L. casei* 189–205
affinity column pools
activation 199
binding ratios 203
FdUMP binding ratios 200, 202
inhibitory ternary complex in 198, 201, 202
native PAGE 201–203
TCA precipitation assay 200, 202, 203
affinity chromatography
folate ligands 190, 191
10-formyl-aminohexyl-Sepharose 191, 193, 197, 198, 204
nucleotide affinants 190
cell-free extracts 204
CM-Sephadex extraction 192–196, 204
earlier procedure 193
electrophoretic methods 191
2-mercaptoethanol protection 201
oligonucleotide binding site 195
Q-Sepharose chromatography 192, 193, 196, 204
summary of process and yields 204
dUMP in 190, 197, 198
reaction catalyzed 47, 189
SDS-polyacrylamide gel electrophoresis 184
specific activities 184
target for chemotherapy 161–174, 189
ternary complex 47–59
active site 52–55, 57
alpha helices in 52, 54
apo enzyme 56, 57
beta bulge 50, 53
beta sandwich 51, 59
beta sheet 49–51, 53, 58
C-terminus in catalysis 57, 58
conformational change 52, 57
crystal structure 49, 58
folate binding site 55
FdUMP binding 50, 53
hydrogen bonding 52
human leukemic 54
inhibition 47
by quinazolines 56
isolation from *E. coli* 49
ligand binding 52, 53, 57
loss of activity, and C-terminus 58
monomeric subunit 49, 50
of *L. casei* 51, 54
ordered binding of substrates 56
PDDF binding 50, 53–55
sequence with monoglutamate substrates 56
sequence with polyglutamate substrates 56, 57
dUMP binding 54, 56
X-ray diffraction 49
Tiazofurin (2-β-D-ribofuranosyl-thiazole-4-carboxamide, NSC 286193)
chemotherapy 75–93, 101, 102, 116
treatment of human leukemia, protocol
allopurinol dose 78, 85, 86
biochemical impact 79
clinical outcome 80, 81
hematological response 80
peak plasma concentrations 83, 84
tiazofurin dose 78, 79, 82
toxicity, infusion on 82–85
down regulation of *ras* oncogene 88, 89

induced differentiation 87–89, 102, 113, 116
induced metabolic cascade 89
on GTP cycle 78, 113, 114
on HL60 cells 91, 102–104, 113
with cholera toxin 103
on human AML 101
on K-562 cells 101
on mouse Lewis lung carcinoma 101
on mouse osteocarcinoma 101
phosphorylation 102
structure 101
synergism with dibromodulcitol 91
synergism with retinoic acid 76, 91–93
Trimetrexate (TMTX)
cell accumulation and toxicity 7
depletion of folates 211
in AML 280
inhibition of DHFR 209, 210
on MTX-resistant carcinoma cells 281
on rat sarcoma cells 281, 282
structure 282
synergism with 5,10-dideazatetrahydrofolate 7

UDP-glucuronate in TS purification 190
dUMP (2′-deoxyuridine 5′-phosphate)
binding to TS 54, 56, 57
in TS purification 190, 197, 198
^{1}H NMR resonance shifts 149
mercuration 143, 147, 153
reductive methylation 141
Urate efflux routes in L1210 cells 68, 69

Verapamil inhibition of
cholate efflux 67, 68, 70
MTX efflux 65, 66, 68, 70
Vinca alkaloids
inhibition of cAMP efflux 64
on MTX cytotoxicity 8
Vincristine
inhibition of MTX efflux 64, 69
on uptake and efflux of cholate 67, 68
selection of resistant CCRF cell line 238
treatment and multidrug resistance 232
Vitamin D catabolite efflux 69, 70
VP16 and CLL lymphocytes 274

Xanthine oxidase in liver, inhibition by allopurinol 85, 86

Zwitterionic compounds efflux 69